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ABSTRACT 
Tryptophan is an essential amino acid that is obtained from the diet. Approximately 98 % of ingested 
tryptophan is metabolized by the enzyme tryptophan 2,3-dioxygenase (TDO). The metabolism of 
tryptophan by TDO is an important determinant of tryptophan bioavailability to the brain for 
serotonin (5-HT) biosynthesis, an essential amine in affective disorders such as depression. Studies 
done on circadian rhythmicity of the enzyme activity have shown that, TDO activity is high during 
the scoto-phase (dark-phase), which is attributable to the de novo enzyme synthesis that occurs 
during this phase. 6-Methoxy-2-benzoxazolinontr-(6-MBOA), a structural analogue of melatonin 
(aMT) was shown to inhibit TDO activity in both the photo-phase (light-phase) and the scoto-phase 
with greater potency during the light-phase. 
Further studies were directed at demonstrating the effects of 6-MBOA on the brain tryptophan 
\ 
hydroxylase (TH) activity, which is a rate limiting enzyme in 5-HT biosynthesis and subsequently on 
J 
5-HT levels. The findings showed that, 6-MBOA induces TH activity with a concomitant rise in brain 
5-HT levels. 
The blockade of 5-HT re-uptake into the presynaptic neuron leads to an increase in 5-HT available 
for the stimulatory action of 5-HT receptors. An attempt to establish whether the administration of 
6-MBOA would block the binding of 5-HT to receptors on the synaptosomal membrane showed that 
Vi 
6-MBO A only inhibits the binding of 5 -HT at specific concentrations. In view of the positive effects 
imposed by 6-MBOA on brain 5-HT levels, urinary 5-hydroxyindole acetic acid (5-HIAA) excretion 
was measured before and after treatment with 6-MBOA. 5-HIAA excretion was found to be 
significantly increased after 6-MBOA treatment. 
Extensive research on the biosynthesis of pineal metabolites has been conducted in the past two 
decades. The pineal metabolites are synthesized from the precursor tryptophan. In order to obtain an 
overall picture of the effect of6-MBOA on pineal indole metabolism, an organ culture technique was 
employed. The results obtained showed that although 6-MBOA administration to rats caused a 
significant increase in aMT production, there was an insignificant increase in NAS production. This 
is an immediate precursor of aMT. Other pineal indoles were not affected at all by 6-MBOA 
administration. Furthermore, the production of pineal NAS and aMT showed an inter-individual 
variation with some animals producing very high, some very low and some produced average levels 
of these two metabolites in both photo and scoto-phase experiments. 
A study undertaken to investigate the circadian rhythm in endogenous aMT production using the 
I 
competitive ELISA technique showed a clear pattern with high levels of aMT produced during the 
dark-phase and low levels ofaMT produced during the light-phase. Furthermore, the administration 
of6-MBOA to rats lead to a significant rise in endogenous aMT production. 
Vll 
CHAPTER! 
LITERA TURE REVIEW 
1.1 INTRODUCTION 
Depressive and anxiety disorders are common and disabling. These disorders are associated with 
significant morbidity and mortality. However, numerous efficacious and safe drugs do exist for the 
treatment of these disorders. The antidepressants are structurally heterogenous with vastly different 
pharmacokinetics and metabolic disposition (Els, 1998). Despite increased. understanding of depressive 
disorder, there remains a substantial clinical need for new and improved therapeutic alternatives to 
manage this condition and related disorders. 
,I 
Depression is a disorder that is associated with feelings of sadness, apathy, inadequacy and 
discouragement. It affects middle and old aged people and its major cause is stress (Harper, 1998). 
It is one of the costly and major health concerns. It is viewed as a more physical p'ain as compared 
to hypertension, diabetes and gastrointestinal problems. Depression is rated by the World Health 
Organization (WHO) as a number one disorder that in developed countries leads to disability. WHO 
1 
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reports that in the year 1990 in developing countries depression was rated the number four cause of 
disability and speculate that by the year 2020 it will be the leading cause of disability (Harper, 1998). 
A South African organization that deals with the disease profiles linked to medication usage ranks 
depression as one of the top five ailments, which include hypertension, cholesterol, diabetes and 
anxiety disorder (Harper, 1998). 
Severe depression is speculated to be genetically linked and is caused by a combination of disorders 
that develop in biologically vulnerable people (Weissman et. ai., 1984). There is evidence that the 
metabolism ofbiogenic amines is disturbed in depressive illness (Badawy and Evans, 1981). However, 
there are regulatory factors for enzymes involved in metabolism of these amines and other 
neurotransmitters (NT's). Serotonin (5-HT) has been shown to play an essential role in the mood 
changes characteristic of this illness (Badawy and Evans, 1981). 
Brain 5-HT has been shown by clinicians and pharmacologists to be decreased in depressed patients 
~ 
and that it increases after treatment with antidepressants (http://www.virtuvites.com ). "The enzymes, 
tryptophan 2,3-dioxygenase (TDO) (Rubin, 1967; Badawy and Evans, 1981) and monoamine oxidase 
(MAO) (Haber et. ai., 1981) which affect the levels of 5-HT are also known to play an essential role 
in depression. 
The pineal hormone, melatonin (aMT) has been reported to be low in depressed subjects (Beck-Friis 
2 
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et. al., 1984). aMT has been shown to have inhibitory effects on TDO (Walsh and Daya, 1994). 6-
Methoxy-2-benzoxazolinone (6-MBOA), a tryptophan derivative and a aMT analogue synthesized 
by seedlings of winter wheat has been shown to increase pineal aMT levels (Yuwiler and Winters, 
1985). These findings imply that 6-MBOA could potentially reduce depression by directly influencing 
the biosynthetic pathway of biogenic amines. 
There are different types of antidepressants and each has its own characteristic mode of action. 
Antidepressants are also characterized by side effects that these impose on individuals. Extensive 
research is thus carried out to elucidate the improved efficacy of antidepressants and reduction of side 
effects, respectively. 
1.2 FACTORS AFFECTING DEPRESSION 
Diagnosis of depression at an early stage is very important. Depressed people can generally be treated 
~ 
on an outpatient basis and maintain performance levels and reduce high cost for hospitalization and 
treatment of other physical and psychologicaf problems resulting from untreated depression (Haper, 
1998). 
Sexual dysfunction may be the result of the period of depression. Sexual dysfunction can worsen 
symptoms of depression ifleft unrecognized or untreated. However, lack of treatment of depression 
3 
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is not only reflected by sexual dysfunction, but there are more untoward effects such as lowered self-
esteem, poor interpersonal relationships and permanent depression episode which are reported to 
occur (Segraves, 1992). From the above speculations, depression appears to be a curable disorder. 
Monoamines play a vital role in affective disorders and in the pathogenesis of these disorders. 
N oradrenergic and serotonergic systems in particular portray differences in mechanisms and pathways 
between depressed and normal subjects. It is important to note that both aMT and 5-HT are part of 
the noradrenergic and serotonergic systems and are both tryptophan derivatives. It is therefore 
essential to discuss the metabolism of tryptophan from ingestion to the production of these 
metabolites. 
1.2.1 TRYPTOPHAN: AN ESSENTIAL AMINO ACID 
In any normal diet, either an animal protein-based or a vegetarian-based trypt9phan diet, tryptophan 
is the least plentiful of all 20 food amino acids. Only about 10 % of dietary tryptophan ehters the brain 
and the rest is used to make (a) various body proteins (b) vitamin B3 (c) 5-hydroxytryptamine (5-HT) 
and most is broken down through a kynurenine pathway (South, 1997). 
4 
~toPhan-----~) Protein 
/ ~ 
Hydroxylase ~ 
/ ~K . / ynurenme 
~ I 
5-0H-tryptophan 
L-amino acid 
decarboxylase, 
pyridoxine 
5-0H-tryptamine Tryptamine 
I 
I 
Nicotinic acid 
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Fig. 1.1 The metabolic pathway o/tryptophan (modified/rom Prange et ai, 1973) 
1.2.1.1 Biochemical metabolism of tryptophan 
A quantitative important metabolic route oftryptophan starts with the oxidation / decarboxylation 
~ 
via liver tryptophan 2,3 -dioxygenase (TDO) to formylkynurenine (Madge, 1996; U chid! et. al., 1992). 
Tryptophan is also directly decarboxylated to tryptamine (Martin et. ai., 1972). A small portion of 
tryptophan is taken into the brain to make 5-HT (Fernstrom and Wurtman, 1973; South, 1997). In 
humans, tryptophan administration increases tryptamine synthesis as high as 25 % of the rate of5-HT 
synthesis and the direct precursor of 5-HT, 5-hydroxytryptophan (5-HTP) does not have any effect 
(Awazi and Guldberg, 1978). Chouinard et. al. (1979) suggested that low doses of tryptophan would 
5 
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increase both synthesis and release of 5-HT, while high doses would increase 5-HT synthesis, but not 
5-HT release. Tryptamine on the other hand, has been shown to playa role in inhibiting firing ofS-HT 
neurons, thus preventing the release of5-HT and reinforcing the detrimental effect of tryptophan at 
high doses. 
The concentration of tryptophan in the 5-HT neuron is the rate-limiting factor for brain 5-HT 
synthesis (Fernstrom and Wurtman, 1971b). Fernstrom and Wurtman (1973) have shown that 
increments in doses of tryptophan cause an increase in 5-hydroxyindoleacetic acid (5-HIAA), an 
immediate metabolite of 5-HT and in 5-HT - containing raphe neurons. This suggests that 5-HT is 
immediately metabolized after release from neurori vesicles or is intraneurally metabolized. Sheard 
et. al. (1972) reported that, high doses oftryptophan and tricyclic antidepressants such as imipramine, 
amitriptyline and clomipramine, inhibit the firing of 5-HT neurons and eventually the release of 5-HT 
onto the postsynaptic receptors. 
1.2.1.2 Tryptophan distribution 
,I 
Tagliamonte et. al. (1971 a) reported that serum and brain tryptophan levels are independent of each 
other. Brain tryptophan levels are also influenced by physiological and diurnal rhythms and this could 
partly influence 5-HT synthesis, but a drastic increase in brain tryptophan does not significantly 
change 5-HT levels. Wurtman et. al. (1967) found tryptophan values in human plasma to be lowest 
6 
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at 2-4 am and increase by 50-80 % to peak values late in the morning or early afternoon. The 
amplitude of tryptophan and other amino acids rhythm tend to relate inversely to its availability in the 
body in rats and mice. Fernstrom and coworkers in 1966 observed that the peak tryptophan levels 
above those daily peaks reported above, occurred about 8-10 hours later than the peak levels in 
humans, a phenomenon probably attributable to the rat's tendency to consume most of its food during 
the hours surrounding the onset of daily period of darkness. 
1.2.1.3 Tryptophan uptake system 
The uptake of tryptophan by the brain is essential because the synthesis of useful indoleamines such 
as 5-HT and aMT is dependent on this amino acid. Tryptophan is unique among other amino acids 
as it is carried in plasma loosely bound to albumin. The binding site of the albumin is shared by non-
esterified fatty acids (NEF A) which can displace tryptophan and this influences the amount of 
tryptophan in free solution (Haber et. al., 1981). Haber et. al., 1981 suggested that the non-esterified 
,I 
fatty acids circulating in serum are almost entirely bound to albumin and these tend to interfere with 
the binding of tryptophan to the protein molecule in vivo. This interaction permits an explanation of 
the paradoxical responses of serum tryptophan to insulin in rats and humans. After carbohydrate 
consumption and insulin secretion, NEF A levels rapidly decrease thus decreasing the levels ofNEF A 
bound to circulating albumin. This allows more tryptophan to become bound to albumin in rats and 
in humans prevents the dissociation of tryptophan from albumin. In rats therefore, serum free 
7 
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tryptophan levels drop, albumin-bound tryptophan rises and total tryptophan levels rise. In humans, 
serum free tryptophan levels also drop, albumin-bound remains unaltered and serum total tryptophan 
decreases slightly. 
Fernstrom and Wurtman (1971b) also showed that tryptophan brain levels are not only dependent on 
the concentration offree serum tryptophan, but also on the concentration of other amino acids sharing 
the same transport system with tryptophan. To support this, Haber et. al. (1981) demonstrated an 
existence of the large neutral amino acids that share a transport system at the blood-brain barrier 
(BBB) which compete with each other for the carrier system. 
The uptake of tryptophan by brain is stereoselective with brain to plasma ratios of approximately 0.25. 
The stereoselective property of the uptake of tryptophan by the brain was shown with experiments 
using D-tryptophan which gave little or no rise in circulating L-isomer occurring in response to an 
injection of the D-isomer. This therefore suggests that uptake of D-trypt~phan by the brain is 
,I 
independent ofL-tryptophan (L-tryp) (Guroffand Udenfriend, 1961). 
1.2.1.4 Physiological role of tryptophan on sleep 
L-tryptophan has been shown by many researchers to induce sedation and changes in sleep patterns 
in both humans and experimental animals. In humans, it has been found that the actions of tryptophan 
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on sleep are not mediated via its metabolite, 5-HT. Hartman (1967) cited that neither a tryptophan-
free nor a tryptophan-rich diet significantly affects total sleep in rats. This was shown by insignificant 
changes in 5-HT as compared to changes seen when 5-HT inhibitors and precursors were used. It can 
therefore be suggested that tryptophan may influence sleep by acting via some tryptophan metabolites 
other than 5-HT. It is therefore important to address the control of tryptophan metabolism. 
1.2.2 HEPATIC TRYPTOPHAN 2,3-DIOXYGENASE (TDO) 
Tryptophan 2,3-dioxygenase (TDO) is a liver enzyme that catalyses the conversion of tryptophan into 
kynurenines. The formation of kynurenines is believed to be the major pathway undergone by 
tryptophan. 
The first discovery of existence of TDO activity in the brain tissue was discovered by Gal et. al. 
(1966) when these authors studied the nature of hydroxylation of L-tryptophC\ll (L-tryp) in vitro and 
obtained unequivocal evidence for the enzymatic formation of Land D-kynurelnne from the 
precursors in rat and pigeon brain homogenates. Tsuda et. al. (1972) furthered this by demonstrating 
oxidative cleavage of L-5-hydroxytryptophan (L-5-HTP) to L-5-hydroxykynurenine in rat brain 
homogenates. Later in 1973, Hirata discovered a similar cleavage of5-hydroxytryptamine and aMT 
by an enzyme partiaIlly purified from brain and pineal gland. 
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a-Methyl-DL-tryptophan which was not known as a substrate was shown to increase TDO activity 
in vivo (Civen and Knox, 1960). Schutz et.al. (1972) demonstrated that at certain concentration, the 
same substrate, a-Methyl-DL-tryptophan stimulated the activity of the enzyme in vitro (Gal, 1974). 
1.2.2.1 Physiological and biochemical properties of TDO 
Hepatic tryptophan 2,3-dioxygenase (EC 1.13.11.11 ,TDO), is a cytosolic tetrameric protein (167 
kDa) containing 2 mol of proto haem IX It catalyses the oxygenative conversion ofL-tryptophan (L-
tryp) to L-formylkynurenine at the expense of 1 mole of molecular oxygen (Lapin, 1980). 
L-tryptophan + Oxygen <=> L-Formylkynurenine 
Stimulation of the enzyme by haem enhances the catabolism ofL-tryp thus making less L-tryp to be 
taken up together with other amino acids such as leucine, isoleucine, valine, tyrosine and phenylalanine 
into the brain and other tissues. In the brain, L-tryp is converted to 5-HT and in some tissues it is 
,I 
utilised for protein and NAD(P)H synthesis and ultimately converted into nucleic acids. In a normal 
protein diet, L-tryp is the least plentiful of all amino acids, therefore it is outnumbered as much as 7 -
9 % in its competition to secure its transport through the blood-brain-barrier (BBB) into the brain 
(Cho-Chung and Pitot, 1967), 
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The enzyme exists in two forms. One form is the already active reduced holoenzyme, and the other 
is the inactive apoenzyme which requires the addition of haem for its activation. The ratio of 
holo:apoTDO indicates the degree of saturation of apoenzyme by haem (Badawy and Evans, 1975). 
The chronic administration of ethanol or phenobarbitone inhibits the activity of rat liver apo TDO and 
subsequent withdrawal of either drug enhances both holo and apoenzyme activities. The guinea-pig 
liver has been shown to contain only one form ofTDO, the holoenzyme. The guinea-pig liver may 
therefore be used as a model for studying holoenzyme activity (Badawy and Evans, 1974). 
TDO is subject to a diurnal rhythm with its peak activity during the pre-dark period and the lowest 
activity towards the end of the dark period in the rat. This circadian rhythm could be due to the 
endogeneous rhythm of aMT and 5-HT production which have peak levels towards the end of the 
dark period (Hard eland and Rensing, 1968). 
1.2.2.2 Biochemical regulation of TDO 
,I 
TDO activity is regulated by a number of factors. Stimulation and inhibition of the enzyme is thus 
dependent on these factors and on different compounds of which the substrate tryptophan is one of. 
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Kynurenic acid i Kynurenine transaminase 
L-tryptophan TDO > N-formylkynurenine --)o~ L-kynurenine 
1 . 3-hydroxy-kynurenme 
Excreted ... 0(;:------ 3-hYdroxylnthranilic acid 
1 
2-acroleyl-3-amino-fumarate 
1 Quinolinic acid 
Nicotinic acid ... o(~---- 1 Nicotinic acidlmononucleo~de 
,I 
Deamino NAD+ 
1 
NADH 
Fig 1.2 L-Tryptophan-Kynurenine pathway ECho-Chung and Pitot (1967)] 
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1.2.2.2.1 Biochemical regulation of TDO by tryptophan 
An increase in availability of circulating amino acid to the brain may be enhanced by one of the three 
peripheral mechanisms: (a) Decrease in TDO activity leading to a deficient hepatic tryptophan 
catabolism. (b) Increased release of protein-bound plasma tryptophan. (c) A decrease in circulating 
plasma neutral amino acids which compete with tryptophan for cerebral uptake system. There is an 
inverse relationship between hepatic TDO activity and brain 5-HT concentration, whereby the latter 
is affected by the availability of tryptophan which is catabolised by the enzyme TDO. An inverse 
relationship between TDO and 5-HT synthesis was proven by experiments in which TDO activity was 
enhanced by acute administration of cortisol or ethanol or by chronic administration of dieldrin, 
ethanol or nicotinamide which resulted in inhibition of the enzyme activity (Badawy et. aI., 1981). 
Knox (1966) hypothesised that the enhancement of activity after tryptophan addition in vitro involve 
the promotion of the conjugation of the apoenzyme with haem and the subseguent reduction of the 
oxidised holoenzyme. Tryptophan loading appears to be more effective than haem addition since the 
addition ofL-tryp leads to a more stable enzyme and enhances protection ofTDO against degrading 
enzymes. In addition to this, L-tryp loading does not interfere with the rate of synthesis ofthe enzyme. 
During haem loading, none of this is observed. It was also suggested that there might be two different 
mechanisms by which TDO activity is enhanced, but that has not been investigated in depth (Badawy 
and Evans, 1974; Badawy and Evans, 1975). 
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The enhancement ofTDO activity by exogenous L-tryp does not depend on RNA synthesis. This was 
found when actinomycin D did not prevent L-tryp effect on TDO activity. On the other hand, ongoing 
protein synthesis does moderately prevent the L-tryp-induced increase in the enzyme activity. This was 
obtained by addition of cycloheximide (protein synthesis inhibitor) (Badawy and Evans, 1973a&b). 
The guinea-pig holoenzyme activity has been shown to be enhanced by treatment withL-tryp (Badawy 
and Evans, 1974). Allopurinol, a specific apoenzyme inhibitor in the rat completely prevents L-tryp 
enhancement ofTDO activity and increases brain L-tryp concentration (Badawy and Evans, 1973b). 
Guinea-pig TDO holoenzyme activity is however blocked by this inhibitor after L-tryp administration. 
This therefore suggests that L-tryp may activate the enzyme by promoting the rapid conjugation of 
an apoTDO protein with its haem activator. Furthermore, large doses ofL-tryp do not cause an early 
activation ofthe rat enzyme whereas smaller doses do so in the guinea-pig liver. It has been reported 
in literature that guinea-pig liver and serum concentrations ofL-tryp are lower than those in the rat 
which could partly explain the higher sensitivity of the former animal to L-tryp treatment (Badawy and 
Evans, 1974). ,I 
1.2.2.2.2 Biochemical regulation of TDO activity by haem 
Administration of haem or its precursor 5-aminolaevulinate enhances the activity of the enzyme 
(Badawy et. at., 1987). Initially, the mode of action of these compounds is to increase the saturation 
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ofthe endogeneous apoenzyme with haem. Badawy and Evans (1975) have shown that haem is slowly 
taken up by the liver because of binding to plasma proteins. These researchers obtained this finding 
after injection of rats with haem and only observed the effect i.e. appearance of saturation of 
apoenzyme by haem, after two hours. The effect was measured by an increase in apoenzyme activity. 
After administration, haem immediately binds to plasma proteins. This binding is then followed by an 
overall increase in the activity of the apoenzyme of which the majority is haem-saturated. TDO plays 
an important role in haem utilisation, therefore any drug which increases TDO activity will eventually 
increase haem utilisation. Activation of TDO by exogeneous haem is not prevented by actinomycin 
D or by puromycin, which are inhibitors of RNA synthesis. These agents block pyrollase activity only 
when 5-aminolaevulinate is administered. This suggests that the steps in haem synthesis beyond 5-
aminolaevulinate synthetase requires the continuation ofmRNA and protein synthesis for activation 
to occur. One such step that has been proven to require mRNA and protein synthesis is the one that 
involves 5-aminolaevulinate dehydratase (Badawy and Evans, 1981). Badawy~and Evans (1975) and 
Knox (1966) have showed that L-tryp enhances activity of rat liver 5-aminolaevulinAte synthetase 
which is the rate limiting enzyme in the biosynthetic pathway of porphyrins and haem. 
1.2.2.2.3 Biochemical regulation of TDO activity by glucocorticoids 
Glucocorticoids have been shown to regulate TDO activity. The administration of a stress hormone, 
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cortisol which is produced by adrenal glands does not show any effect on the ratio ofholo:apoTDO. 
The ratio resembles that of the basal enzyme (less than 1), thus suggesting about half of the newly 
synthesized apoenzyme becomes conjugated with haem whereas on the other hand L-tryp activated 
enzyme exhibits a larger degree of haem saturation. Moreover, cortisol does not cause any initial 
saturation of the apoenzyme with haem but produces a great rise in the total TDO activity while 
maintaining holo:apoenzyme ratio close to that of the basal enzyme (Badawy and Evans, 1975). 
1.2.2.3 Inhibition of TDO activity 
Most of the literature has reported that TDO substrate at acidic and at basic pH with concomitant 
shifts in substrate maximum (SmaJ and the substrate concentration beyond the maximum activity 
(V maJ, substrate inhibition of TDO activity is observed. This shows that the L-tryp-kynurenine 
pathway can be regulated through substrate inhibition. 
Madge et. al. (1996) showed that a series of novel indoles have inhibitory effects on'TDO activity 
with some members having 5-HT reuptake inhibitory activity. These compounds thus lead to 
increased levels ofL-tryp and 5-HT in cerebrospinal fluid (CSF) which could be vitally important for 
antidepressant therapy. To support this, Walsh and Daya (1997) showed that TDO activity is 
regulated differentially by the indoles, aMT and 5-HT. aMT is a competitive inhibitor ofTDO and 5-
HT is predominantly an allosteric inhibitor. In the presence of 5-HT, aMT effects are nullified, but 
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aMT alone is the most potent inhibitor of TDO. Badawy and Evans (1981) showed that MAO 
inhibitors are weak inhibitors of TDO activity. 
Binding of substrates and inhibitors to the enzyme has been extensively studied by Uchida et. aI. 
(1985) using the infrared carbon monoxide (IR-CO) stretch band(s) of compound-bound 
carbonmonoxy TDO. The infrared spectra for TDO-CO in the presence of5-hydroxytryptophan (5-
RTP: reported as a non-competitive inhibitor) was similar to that of the substrate bound TDO-CO, 
while the one in the presence oftryptamine (competitive inhibitor) was different. The infrared spectra 
analysis therefore indicate that there are two types of catalytic site-binding inhibitors. The first type 
-" 
to which 5-RTP was found to belong to, binds to the catalytic site with a correct configuration similar 
to that of substrates and the second type e.g. tryptamine, with an inaccurate configuration with the 
enzyme. 
Nitrogen in the indole ring of the substrate, L-tryp, appears to be indispensable for a molecule to bind 
~ 
to the catalytic site because the catalytic site-binding analogs studies thus far conserve the NH group 
whereas a substitution ofNH by N-CR3 prevents the molecule from binding to the catalytic site. This 
suggests that the NH group plays an essential role in positioning a molecule at a certain point near the 
Fe-CO group via a specific and presumably strong hydrogen-bonding with an acidic amino acid side 
chain (Uchida et. aI., 1992). 
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It has been demonstrated that an enzyme reaction proceeding via a hydro-peroxide, the dissociation 
of the N-H that is expected to occur, would be facilitated by an interaction with a strong hydrogen 
attracting group. Conservation of an acid side chain, CH(NH2)COOH is considered a very important 
component for binding into the catalytic site and to make a correct configuration suitable for the 
reaction to occur, but variation of protein side chains might lead to different efficiencies of enzyme 
reactions. If an acidic side chain of a molecule is incomplete, the NH group of the indole ring and the 
hydrogens in the fifth and sixth position exist, the molecule will be pinned to the catalytic site but no 
reaction will occur (Nakagawa et. al., 1976). 
Sugiyama et. al. (1967) and Beer et. al. (1954) reported that, generally, derivatives with an electron 
donating substituent i.e, hydroxy (OH) or methoxy (CH30) at position 5, are more labile to oxygen 
than the ones without it. It has been suggested that the structural flexibility needed for the catalytic 
reaction is significantly reduced. From this report, it seems that there are two types of catalytic-site 
binding inhibitor. The first type is a substrate analogue that lacks an Clfcurate configuration 
appropriate for the catalytic reaction to occur due to an absence of functional grodps for proper 
interactions with the protein part at the haem pocket of the catalytic site. The second type is the 
substrate analogue containing the correct functional groups and take a correct configuration for the 
reaction and is potentially reactive as the first type but cannot act as a proper substrate. The functional 
groups of this analogue make additional interactions with the protein side chain(s) in the catalytic site 
and that leads to reduction in catalytic potential of the haem pocket (Uchida et. al., 1992). 
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1.2.3 SEROTONIN 
1.2.3.1 The biosynthetic pathway of serotonin 
5-HT is synthesised from tryptophan. Tryptophan from the circulation is taken up to the brain and the 
enzyme tryptophan hydroxylase converts tryptophan to 5-hydroxytryptophan (5-HTP). TH is a rate 
limiting enzyme in 5-HT synthesis (Carlson et. al., 1972). Under normal conditions, the saturation of 
brain TH portrays regional differences (Meek and Lofstrandh, 1976) and is usually not saturated with 
its substrate tryptophan, thereby very sensitive to minor alterations in tryptophan concentration 
(Bengtssonet. ai., 1991). Synthesis of5-HT is not only subjected to availability of tryptophan but also 
depends on the redox state of the essential cofactor tetrahydrobiopterin (BH4) (Gal and Patterson, 
1973; Bengtsson et. ai., 1991).5-HTP is then converted to 5-hydroxytryptamine (5-HT: serotonin) 
by the enzyme amino acid decarboxylase which uses pyridoxine as a cofactor. 
" 
1.2.3.1.1 Discovery of serotonin precursors: Tryptophan and 5-hydroxytryptophan 
The first experimental demonstration that tryptophan is the dietary precursor of 5 -HT came from the 
studies done by Udenfriend and colleagues in 1956. These researchers demonstrated that the 
administration of radioactive tryptophan to Bufo marinus and the rabbit, led to the formation of 
radioactive 5 -HT. An investigation for enzymatic hydroxylation oftryptophan to 5 -hydroxytryptophan 
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Fig. 1.3 The biosynthesis of serotonin (5-HT) 
CHAPTER 1 
(5-HTP), the direct precursor of 5-HT was first directed towards a microorganism called 
Chromobacterium violaceum because chemical analysis of violacein, a purple pigment produced by 
this organism had revealed the existence of a 5-hydroxyindole moeity (Fernstrom and Wurtman, 
1973). 
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Mitoma and coworkers in 1956 managed to isolate 5-HTP from the growth medium. Resting cells of 
this microorganism were then incubated with L-tryp and produced sufficient amounts of 5-HTP to 
be detected by the nitrosonaphthol colorimetric assay designed by Udenfriend and his colleagues in 
1955. Hydroxylation ofL-tryp in a cell-free system was reported for the first time by Cooper and 
Melcer (1961) in mammalian intestinal mucosa. This hydroxylation was found to be an artifact by 
Renson and colleagues in 1962 since this was a non-enzymatic hydroxylation i. e. of no physiological 
importance. The first unequivocal demonstration of enzymatic formation of 5-HT using a cell-free 
system was achieved by using rat liver homogenate in the presence oflarge concentrations ofL-tryp 
(1.6 X 10-2 M) by Freedland and coworkers in 1961 (Fernstrom and Wurtman, 1973). 
1.2.3.2 Serotonin function 
5-HT, dopamine (DA) and nor-adrenaline (NA) are the three main monoamine neurotransmitters 
(NT's). Tryptophan is the precursor of 5-HT whereas both DA and NA are detived from tyrosine. 5-
,/ 
HT is used by body parts such as the brain, blood platelets and some intestinal lining cells is produced 
in the neurons. Serotonin cannot pass the BBB, therefore, 5-HT synthesized in the brain cannot be 
taken outside the brain. The precursor of 5-HT, tryptophan, can pass the BBB through a carrier 
protein whereas 5-HTP crosses BBB independently (South, 1997). 
5-HT is one of the major brain NT. Studies with humans and experimental animals have shown that 
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5-HT nerve circuits promote feelings of well being such as calmness, confidence and concentration. 
5-HT neural circuits also help counterbalance the tendency of brain dopamine (DA) and nor-
adrenaline (NA) to encourage overousal, fear, anger, tension, anxiety, aggression and sleep 
disturbances (South, 1997). 
1.2.3.3 Physiological factors affecting brain serotonin levels 
Brain tryptophan content is the most essential factor in determining the rate of 5-HT synthesis because 
the rate limiting enzyme in 5-HT synthesis, tryptophan hydroxylase (TH) is not always saturated with 
tryptophan. It has been shown that both small and large changes in concentration of brain tryptophan 
alter the rate of synthesis of 5-HT. In rats, after tryptophan administration, a slight increase in 5-HT 
concentration is observed but the brain 5-HT turnover increases markedly and the evidence for that 
is the rise in brain 5-HIAA production (Moir and Eccleston, 1968). 
1.2.4 MITOCHONDRIAL MONOAMINE OXIDASE (MAO) ,I 
Monoamine oxidase (MAO) is a mitochondrial membrane that is involved in de aminating 5-HT to 5-
hydroxyindoleacetic acid (5-HIAA). 
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1.2.4.1 Physiological and biochemical properties or MAO 
MAO (Ee 1.4.3.4), an oxygen oxidoreductase deaminates a monoamine into an aldehyde (Barman, 
1969). The enzyme catalyses the following reaction: 
RCH NR' +0 +H O----'>~RCHO+NHR' +H 0 
2 2 2 2 2 
MAO is an integral protein embedded in a phospholipid structure required for activity in the outer-
mitochondrial membrane (Sottocasa et. al.,1967; Edelstein and Breakfield, 1986). The enzyme 
appears to be a dimeric containing polypeptide chains of similar molecular weight (± 60 000), only 
one of which contains a covalently bound F AD cofactor (Oreland et. al., 1973; Salach, 1979; Edelstein 
and Breakfield, 1986). Bonnefil et. al. (1981) showed that sialic acid resi.due may be required for the 
activity of MAO, indicating that glycosylation of the molecule may occur (Houslay and Marchmont, 
1980). Edelstein and Breakfield (1986) supported those studies by showing that MAO subunits 
\ 
appear to be glycoproteins. Y oudim (1976) and Salach (1979) hypothesized that MAO may contain 
,I 
and depend on iron for activity, but Weyler and Salach (1981) showed that MAO only requires iron 
for its activity but does not contain it. These authors found that highly purified active MAO molecules 
do not contain iron but iron deficiency in vivo results in a loss of activity (Bonnefif et.al., 1981). 
Dixon (1958) showed that alkaline pH destroys the enzyme activity. This author discovered a linear 
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increase of MAO activity in pig liver between pH 5 - ± 7.5 and that the activity is time dependent when 
tyramine is used as a substrate. The optimum temperature was found by Sumner and Myrback to be 
between 30 -39°C. The Michaelis constants of MAO with substrates, benzyl amine and octylamine 
from human placenta have been found to be 3.3 x 10-5 and 4.3 x 10-5 respectively at pH ranges 8.2-
8.5 at physiological temperatures (Barman, 1969). From these two authors it can be hypothesized 
that the pH for optimum MAO activity depends on the species used. Wyatt et. al. (1973b) reported 
that mitochondrial MAO activity in human platelets has some similarities in substrate and inhibitor 
characteristics to MAO activity in brain and other tissues. 
Zeller (1951) discovered that the good substrates are amines with an aromatic ring. In general, 
primary, secondary and tertiary amines, tryptamine derivatives and catecholamines are oxidised 
(Barman, 1969). Phenylethylamine, tyramine, hordenine, adrenaline and indolethylamine shown in fig 
1.4 are also oxidised. In the case of tyramine, substitution in the fourth position leads to a higher 
degradation velocity than in the third and second positions and the oPAosite is true for the 
corresponding methoxyl derivatives (-OCH3) (Zeller, 1951). The descending ordJr of the best 
substrate for the enzyme is from primary >secondary > tertiary amines. The quaternary structure is 
not oxidised at all by MAO. However, the enzyme isolated from human placenta is found to attack 
primary amines only and an increase in chain length of simple alkyl amines results in increased affinity 
(Barman, 1969). The action of MAO is prevented by a methyl group on carbon one ofthe substrate 
and that is of considerable pharmacological importance (Dixon, 1958). 
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MAO activity increases with age in human brain, plasma and platelets (Robinson et. al.,1972; Nies 
et. a1.1973a; Robinson, 1975; Grinna, 1977) proposed that this increase may be due to an increase 
in cholesterol levels of mitochondrial membranes during aging. In contrast to this, in rats, for the first 
weeks, following birth, the central catabolism of 5-HT is much faster than during the adult life and 
that this is due to an increase in MAO activity in tissues from young rats (Haber et. ai., 1981). 
Phenylethylamine 
OH-< rH,CH,NH2 
'---------" 
Tryptamine 
[
CH
2
C
H;NH2, 
OH--< rH2CH2N(CH3)2 Indolethylamine 
'-----' 
Tyramine 
0' 
Hordenine 
Fig.l.4 Amines with aromatic rings (good substraJes for MAO) 
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1.2.4.2 Mode of action of MAO 
After the release of 5-HT from storage sites, it is immediately metabolised by MAO to an unstable 
metabolite, 5-hydroxyacetaldehyde. This metabolite is converted to 5-hydroxytryptophol and 5-
hydroxyindoleacetic acid (5-HIAA) by the enzyme alcohol dehydrogenase (Cardinali, 1981). 
H 
H 
S-hydroxytryptamine (SHT) 
HO l.MAO 
trCHO 
H 
5-hYdroxyindO~dehdye HlJ()/ H ' I CHzClIzOH ~ 't----,--ClIzClIzNlIz J 
H 
5-hydroxytryptophol H 
S-hydroxyindoleacetic acid 
(SHIAA) 
Fig. 1. 5 The catabolic pathway of serotonin (5-HT) 
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1.2.4.3 MAO isoenzymes classification 
Existence of two types of active MAO have been identified. One type is termed MAO-A and the other 
MAO-B (Reiter, 1989). 
1.2.4.3.1 Biochemical and physiological differences between MAO isoenzymes 
The two forms of active enzyme differ in optimum pH optima, sensitivity to various compounds and 
treatments, dependence on phospholipids, degree of glycosylation, immunoreactivity and distribution 
in the mitochondrial membrane. In addition, the two forms of MAO have been physically separated 
by ion-exchange and immunoaffinity chromatography and the flavin-containing subunits have been 
shown to differ in molecular weight and I-dimensional peptide maps by sodium dodecyl sulfate 
(SDS)-polyacrylamide gel electrophoresis. Furthermore, these two forms of MAO appear to be 
independently regulated. Within a single tissue, the two forms are found in diiiferent concentrations 
(Edelstein and Breakefield, 1986). ,I 
The two forms of MAO can be distinguished on the basis of their substrate speQificity, inhibitor 
sensitivity, kinetic parameters and protein structures. Furthermore, phospholipids have been implicated 
as playing important roles in the activity, inhibitor specificity and heterogeneity of the enzyme 
(Y oudim, 1972 and Kroon and Veldstra, 1972). These properties were used to study the molecular 
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mechanism(s) by which glucocorticoid hormones and aging alter MAO activity in vivo. Roth et. al. 
(1976) and Groshong and Baldessarini (1977) showed that fibroblasts, predominantly contain MAO-A 
and Donnely et. al. (1976) reported that also neurons are predominated by MAO-A. Cellular aging 
in the presence of these hormones resulted in inhibition of MAO activity, and this effect was only 
shown in MAO-A (Tabor, 1954). 
Both forms have been shown to readily deaminate tryptamine and tyramine in vitro and inhibited by 
similar concentrations of pargyline. MAO-B metabolises dopamine but not serotonin or other 
catecholamines and deprenyl is a selective inhibitor ofMAO-B both in vitro and in vivo. MAO-A on 
the other hand deaminates serotonin and noradrenaline, but not dopamine and is selectively inhibited 
by clorgyline (Edelstein and Breakefield, 1986). 
1.2.6 5-HYDROXYINDOLE ACETIC ACID (5-HIAA) 
Tryptophan is a dietary precursor of 5-HT and 5-hydroxyindole acetic acid (5-illAA~ respectively. 
5-illAA was discovered in the plant, Piptadenia peregrina which produces large amounts ofN,N-
dimethyl-5-hydroxytryptamine and other 5-hydroxyindoleamines. Mammalian tissues which are rich 
in monoamine and aldehyde oxidases indicate that oxidation of 5-HT to 5-illAA might be the major 
route of its metabolism (Udenfriend et. aI., 1956). 5-illAA is a normal constituent of mammalian 
urine. An increase in 5 -illAA in urine ( milligram) indicates an appreciable portion of tryptophan being 
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metabolised via the 5-hydroxyindole route (Udenfriend et. al., 1956). 
Administration of 5-hydroxytryptophan (5-HTP), 5-HT and 5-HIAA leads to excretion of these 
compounds as 5-HIAA in the urine. 5-HIAA may either be derived from these amines or from 
decarboxylation of 5-hydroxyindolepyruvic acid (5-HIP A) which may arise by transamination of 5-
HTP (Udenfriend et. aI., 1956). Contractor (1966) reported that 5-HIP A is very unstable and is 
unlikely to be present in the urine. Iflarge amounts of this acid excreted in the urine are from 5-HT, 
then the amounts excreted reflects the secretion of the amine (Udenfriend, (1956). Eccleston et. al. 
(1964) suggested that inhibition of 5-HTP decarboxylation results in accumulation of the substrate 
(5-HTP) and subsequent reduction in 5-HT and 5-HIAA respectively. 
Considerable increase in tryptophan and 5-HIAA in different CNS compartments such as the whole 
brain, CSF, striatum and striatal extracellular space after injections ofL-tryp (50 mg/kg) have been 
shown (Sarna et. al., 1991). Commensurate accessions in both tissues and extrafellular compartments 
on tryptophan levels and in 5-HIAA concentrations are subsequently reported and thes~ increases are 
hypothesized to be predominantly of endothelial cell 5-HT metabolism origin (De Simonie et. al., 
1987). 
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1.3 THE PINEAL GLAND 
1.3.1 The anatomy of the pineal gland 
The mammalian pineal gland is a glandular structure derived as an evagination of the neural tube 
(Kappers, 1965). In the rat, the pineal appears as a neuroepithelial protrusion from the roof of the 
diencephalon, the area between the habenular and posterior commissures. Its connection with the 
commisural region is through the pineal stalk. The gland is composed of two parenchymal cell types, 
the pinealocytes and intestitial cells (Wartenberg and Gusek, 1965), both types are of neuroectodermal 
origin. The pinealocytes are the neurosecretory cells of the gland. The rat pineal is highly vascularised, 
its major blood supply being provided by branches of the posterior choroidal (Gladstone and Wakely, 
1940) and posterior cerebral (Hodde, 1979) arteries. Venous drainage occurs via the distal end of 
the great cerebral vein into the superior sagittal sinus (Hodde, 1979). 
,I 
The pineal gland is also known as the "corpuspineale" has been called a neuroendocrine transducer 
because of its important role in photoperiodism. Within the pineal, the neural (photic) information is 
transduced into a hormonal input (Reiter, 1980). The mammalian pineal gland responds to the photic 
information via the lateral eyes whereas in some reptilian and avian species photoreception is via 
penetration through the scalp. Mammals depend on neural connection between the eyes and the gland 
that assimilates the photic information. The neural connection between the eyes and the gland 
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Figure 1.6 The dorsal view of the rat brain showing the location of the pineal gland (Rowett, 
1960) 
I 
include peripheral sympathetic axons which form pineal distinct nervii conarii that penetrate the apex 
of the gland (Kappers, 1960 and 1965). In some few species such as the monkey, the parasympathetic 
innervation predominates (Kenny, 1961). The pineal gland is mainly dependent on autonomic neural 
information derived from the sympathetic nervous system for its hormonal input (Wurtman et. at., 
1965; Reiter and Hester, 1966b; Reiter, 1980; Moore, 1978). 
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Figure 1.7 Schematic representation of the sensory input pathway and the effect of light 
and dark on the synthesis of the various indoleamines in the pineal gland (Reiter, 1989) 
,I 
1.3.2 THE PINEAL INDOLES BIOSYNTHETIC PATHWAY 
The pineal gland is an outgrowth of the ectodermally derived eNS (Reiter, 1980). The metabolism 
of indoleamines in the pineal gland has reviewed enormous interest after the past three decades. The 
major compound of the pineal gland, aMT has attracted a lot of attention. 
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aMTissynthesizedfromtryptophan, via5-HT(Axelrod, 1974; Klein, 1974; Quay, 1974). Tryptophan 
is taken up from the blood and is hydroxylated in the presence of the tryptophan hydroxylase (TH) 
enzyme (Lovenberg et. ai, 1967) to tryptophan hydroxylase and decarboxylated by aromatic amino 
acid decarboxylase (Lovenberg et. aI., 1962) to form 5-HT as shown in figure 1.3. 5-HT has been 
previously proposed as the pineal hormone (Albertazzi et. al., 1966) because of its high concentrations 
in the pineal gland (Quay and Halevy, 1962) but it was found later not to be the case. It was 
discovered that although high concentrations of 5-HT were obtained, the amount released was 
negligible in terms of total amount available in the body (Reiter, 1980). 
5-HT is then taken up by pinealocytes and is subsequently acted upon by N-acetyltransferase (NAT) 
resulting in formation of N-acetylserotonin (NAS) (Klein and Weller, 1970). NAS is then 0-
methylated by hydroxyindole-O-methyltransferase (HIOMT) to form aMT (Axelrod and Weissbach, 
1960). The methyl group for the last enzymatic step is provided by S-adenosylmethionine. There are 
some 5-HT derivatives produced in the pineal gland. MAO enzyme acts on 5-HT and results in 
, 
formation of an unstable metabolite, 5-hydroxyindole acetylaldehyde. This metabolite is ~ither oxidised 
to 5-hydroxyindole acetic acid (5-HIAA) or reduced to 5-hydroxytryptophol (5-HTOH) (Quay, 
1974). HIOMT methylates 5-hydroxytryptophol to 5-methoxytryptophol (McIsaac et. ai., 1965). 
1.3.3 Metabolic fate of pineal indoles 
aMT (Rollag and Niswender, 1976) and possibly 5-MTOH (Wilson et. ai., 1978) are released from 
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Figure 1.8 The biosynthetic pathway of the pineal iodoles (Reiter 1981) , 
,I 
the pineal gland into the systemic circulation. However, if the pineal indoles have the primary site of 
action on the brain, then another potential route of transfer becomes apparent, namely the 
cerebrospinal fluid (CSF). 
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The diurnal aMT rhythms in the blood are paralled by a similar pattern of urinary excretion (Lynch 
et. ai., 1975). The rhythm in the CSF is more pronounced than in the plasma. This may imply that 
aMT is normally released either directly or indirectly into the CSF, but further investigation is required 
on this hypothesis (Hedlund et. aI., 1977). However, Rollag et. al. (1978) suggested that blood is the 
normal route of release of pineal aMT. In view ofthis, CSF appears to be the more favorable reservoir 
for aMT because via this route the problem of rapid deactivation of these substances by the liver is 
circumvented. 
aMT, is metabolised in the liver to 6-hydroxymelatonin which is conjugated to either glucuronide (20 
- 30 %) or to sulphate (60 - 70 %). The main metabolite to be excreted in the urine is 6-
sulphatoxymelatonin. It appears that there is significant correlation between nighttime aMT peak 
levels and 6-hydroxymelatonin excreted from the human urine (Markey et. aI., 1985). From this, one 
can conclude that excretory aMT can be a measure of aMT production. 
1.3.4 Endocrinology of the pineal gland 
,I 
The pineal gland regulates endocrine organs mostly via the neuroendocrine axis of the photoperiod 
and adjusts the activity of the hypothalamo-hypophyseal system accordingly. This interaction is made 
possible by means of hormonal input produced and secreted by the pineal gland (Reiter, 1980). Two 
hormones have been identified to playa role in the endocrine function of the pineal gland. These are 
indoleamines and polypeptides. Both hormones are synthesized and secreted from the pineal gland. 
The indoleamines are derived from tryptophan and polypeptides from various amino acids. 
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The pineal gland has very high concentrations of tryptophan hydroxylase (TH) and due to this, there 
is a greater potential for the pineal gland to produce hydroxyindoles than any other tissues in the 
mammalian body (Reiter, 1980). Furthermore, the gland contains high levels of 5-HT per mg tissue, 
as compared to any other body organs (Quay, 1962 and Saavedra et. at., 1973). One other factor 
that makes the pineal gland to be unique is the N-acetylserotonin (NAS) which is the direct precursor 
of aMT. aMT was discovered by Lerner and colleagues in the late 1950's when these authors were 
exploring the effects of pineal principles on amphibian pigment cells and attempted to extrapolate 
these findings to treatment of human pigmentary disorders (Lerner and Case, 1959). During the 
course of their study, these scientists identified the chemical structure of the pineal substance that 
aggregated amphibian melanosomes, N-acetyl-5-methoxytryptamine and named this compound 
melatonin (aMT) (Lerner et. at., 1958) as it is known to date. 
1.3.5 Regulation of pineal aMT production 
,I 
The pineal principal hormone, aMT , is regulated by light:dark cycles acting via the hypothalamic 
suprachiasmic nucleus (SCN). Pineal regulation is independent of sleep. In mammals, light and 
darkness perceived by the eyes synchronises the circadian activity of the gland whereas in birds light 
directly penetrating the skull influences pineal function (Reiter, 1980). The pinealocytes receive 
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sympathetic nerve endings which release the neurotransmitter (NT) nor-epinephrine (NE) during 
darkness. The NT acts on adrenergic receptors and determines the uptake of tryptophan and the 
synthesis of aMI from the precursor 5-HT after different enzymes have been activated. Adrenergic 
receptors have been shown to potentiate the adrenergic receptors which are linked to adenyl ate 
cyclase (Klein et. a!., 1983a), via a stimulatory guanine-nucleotide binding protein (Gs protein) 
(Helmreich and Pfeuffer, 1985). However, a-adrenergic receptors are coupled to adenyl ate cyclase 
system which in tum is stimulated by a-agonists. In contrast, a-adrenergic receptors can be inhibitory 
to adenyl ate cyclase in the presence of an appropriate agonist (Lefkowitz and Caron, 1985) and via 
an inhibitory guanine nucleotide binding protein. (Helmereich and Pfeuffer, 1985). After NE 
stimulation, the synthesis of intracellular secondary messenger, cyclic AMP (cAMP) is amplified 
leading to aMT synthesis (Reiter, 1991 b). 
During light periods, circulating catecholamines are augmented and a-adrenergic receptors tend to 
lose sensitivity, i.e. a-adrenergic receptors tend to be down-regulated by veV high concentrations 
of catecholeamines. Furthermore, Sweat et. al. (1986) postulated that high aMI levels at night may 
restore the lost a-adrenergic receptor sensitivity caused by catecholamines. 
Apart from sympathetic innervation, the pineal also receives nerve fibers from the CNS. In this case 
the NT's are either peptides e.g.neuropeptide Yor acetylcholine. The cell bodies of these neurons are 
located in different nuclei ofthe brain (Korf and Moller, 1983). The function of this central innervation 
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is currently being investigated and is probably related to additional brain modulation of pineal function 
(Moller et. aI., 1992). 
1.3.6 Role of circadian rhythm on pineal aMT production 
There has been extensive research done on the effect of photoperiod on pineal aMT production and 
most findings indicate that light suppresses the endocrine activity of the pineal gland whereas darkness 
stimulates the production. Both light and darkness playa vital role in the biosynthetic activity and 
endocrine capability of the pineal gland. High concentrations of aMT in the blood and in the pineal 
during the dark period has been observed. 
Reiter (1980) totally agrees with the studies pursued for the last two to three decades that the 
vertebrate pineal gland is required for photoperiodic responses that adjust physiological strategies 
during different seasons of the year and that daily injections of aMT at a proper circadian time can 
account for the pineal activity (Stetson and Watson-Whitnyre, 1986). 
~ 
Klein (1978) observed that in mammals, excluding man, aMT rhythm is disturbed by.constant light 
exposure but persists when animals are kept under constant darkness for prolonged periods. Reiter 
(1980) reported an increase in aMT production during dark periods. 
Lewy and Sach (1992) reported that during and immediately after a change to night-shift work or 
travel across time zones, secretion of aMT depends more on the biological clock than on the light: dark 
cycles. Improvement of performance and synchronization ofthe onset of sleep in shift workers is 
38 
CHAPTER 1 
currently being investigated. 
1.3.7 Distribution of aMT 
For several years after the discovery of aMT, aMT was believed to be secreted solely from the pineal 
gland, but this was proven wrong. aMT was found to be present in body organs such as the gut and 
the brain (Raikhlin et. aI., 1975). Administration oflarge doses of tryptophan leads to an increase in 
serum aMT levels but not NAT and HIOMT activities (Yaga et. al., 1993). 
aMT is found in significant concentrations in several body fluids (Ozaki and Lynch, 1976; Rollag and 
Niswender, 1976) and small amounts ofunmetaboli~sed aMT are excreted in the urine (Lynch et. al., 
1975). 
1.3.8 Pineal aMT on gonadotropic system 
Small animals such as the rodents generally reproduce when environmental conditions are favorable. 
Light: dark cycles have been shown to influence reproduction of many animals ipcluding rodents. The 
laboratory rat has been used as the model for mammalian research experiments, but Js opposed to 
other laboratory animals, it responds minimally and unconclusively to the maneuvering of the pineal 
gland and this therefore makes it to be a poor animal of choice for testing the pineal-gonadal 
interactions (Reiter, 1974). Syrian hamsters are regarded as excellent models for measuring alterations 
in reproduction system due to manipulations of the pineal gland (Reiter, 1974). The earliest reports 
on anti-reproductive effects of aMT were shown in early 1960's. Tamarkin in 1976 made a 
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breakthrough by showing that the inhibitory effect of aMT on gonadotropic system depends on time 
of day of administration of aMT. Tarmakin discovered that, aMT injection is effective when done late 
during the the light phase at 14 hours light: 10 dark hours cycle. The insensitivity of laboratory 
animals on early morning injections was due to endogeneous peak levels of aMT occuring at 04:00 
during the dark phase of the light: dark cycle (Panke et. al.,1978; Panke et. ai., 1979; Tamarkin et. al., 
1979). Reiter (1980) suggested that when aMT acts on its receptors, it down regulates these to any 
additional aMT for a certain period of time. Hence early in the light phase, aMT is ineffective in 
altering reproductive physiology since its receptors are down regulated. However, by late afternoon, 
receptors have regenerated their potential to respond to aMT. Tamarkin et. al. (1979) reported that 
aMT receptors appear to regenerate at about 6.5 hours after lights are switched on. Animals receiving 
aMT injections should also possess an intact and sympathetically innervated pineal gland (Tamarkin 
et. aI., 1976). 
Pinealectomy (Reiter, 1974) or light deprivation (Reiter, 1971) have been shown to have no effect 
~ 
on growth of reproductive organs in rats. 
,I 
1.3.10 The pineal and MAO 
The pineal parenchymal cells and sympathetic nerves that innervate the gland contain 5-HT. 5-HT 
within the nerves probably originates in the parenchymal cells and enters the nervous system via the 
amine reuptake mechanism. Most of the 5-HT synthesized within the pineal gland is probably 
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converted to aMT and its metabolites. Apparently, only the sympathetic nerves that innervate the 
pineal contain MAO-A which specifically metabolises 5-HT and norepinephrine (NE). Experiments 
on this hypothesis were done following sympathectomy ofthe rat pineal gland, the activity toward 5-
HT was reduced by 70 % while only minimal changes toward tyramine metabolism were observed. 
Moreover, MAO activities of human sympathetic trunk: and pineal gland were evaluated for the 
presence of MAO-A and MAO-B enzymes with tyramine as the substrate, two forms were evident. 
Sympathetic nerves contained mainly the clorgyline sensitive enzyme (MAO-A), the pineal gland on 
the other hand contained MAO-B which is resistant to inhibition by clorgyline. These two observations 
had two implications. Firstly, the transmitter NE is preferentially deaminated within the adrenergic 
nerve endings not within the pineal gland since the required enzyme for deamination is absent. 
Moreover, the adrenergic nerve endings within the pineal also have the capacity to metabolise 5-HT 
that finds its way into the neuron. Secondly, the virtual absence of MAO-A in pineal cells is consistent 
with the view that aMT and not 5-HT is the end product of tryptophan metabolism in the pineal cells. 
It appears that 5-HT metabolism would be unaltered in the pineal gland cells after either inhibitor, since 
" deamination is not a major pathway for 5-HT in this tissue (Neff et. al., 1974). 
41 
CHAPTER 1 
1.4 6-METHOXY-2-BENZOXAZOLINONE (6-MBOA) 
6-Methoxybenzoxalinone (6-MBOA) was first isolated from com and was originally considered as an 
insect antifeedant (Smissman et. al., 1957). It was subsequently isolated from sprouted grass (Sanders 
et. ai., 1981) when studied to find dietary constituents which were gonadotropic in the vole Microtus 
montanus (Negus and Berger, 1977; Negus et. ai., 1977). The compound was then found to be 
gonadotropic using intraperitoneal injections under laboratory conditions. 
1.4.1 Biochemical synthesis of 6-MBOA 
6-MBOA is derived from 2,4-dihydroxy-7-meth9xy-2H-l,4-benzoxazin-3(4H)-one (DIMBOA). 
DIMBOA is a defensive factor of maize and wheat seedlings against microorganisms and insects. It 
is stored as its glucoside and released at wounded sites by a glucosidase (Niemeyer, 1988; Wahlroos 
and Virtanen, 1959). In an aqueous solution, near neutral pH, DIMBOA has been reported to rapidly 
decompose in vitro to form an anti-insect substance, 6-MBOA and formic acid (Woodward et. ai., 
1978; Kumar and Chilton, 1994). At longer photoperiods (summer), the convetsion rate ofDIMBOA 
,I 
to 6-MBOA in maize tissue is increased. 
DIMBOA is abundantly present in the primary glucoside in young seedlings and vegetatively growing 
plants (Berger et. ai, 1981). Plant injury coincident with grazing evokes the release of enzymes that 
rapidly convert DIMBOA to 6-MBOA (Nelson and BIom, 1992). Other detection of6-MBOA in the 
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diet is an indication that the growing season has initiated and that food is readily available (Nelson and 
Biom, 1992). 
1.4.2 Effect of 6-MBOA on gonadal function 
Most research on 6-MBOA has concentrated on determining the effect of this compound on gonadal 
function. Seasonal breeding involves the availability offood to animals. Mos~seasonal breeders rely 
on photoperiod to link season and breeding (Sadleir, 1973) and the transduction mech~nism is mainly 
the pineal gland (Reiter, 1980). 
The synthesis of aMT exhibits a circadian rhythm controlled by the NE stimulation of Be 
adrenoreceptors in the pineal gland leading to stimulated activity of the enzyme activity N-acetyl-5-
hydroxytryptamine (NAT) (Axelrod, 1974; Klein, 1974; Deguchi, 1982). Animals living in 
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environments in which light is not closely related to food and warmth must use other factors to control 
reproductive activity (Yuwiler and Winters, 1985). 
The mountainous habitat of the short lived Montane vole, Microtus montanus is characterized by 
overcast skies, low levels oflighting and a snowpack (Yuwiler and Winters, 1985). In 1981, Berger 
et. al. reported that it is rather the ingestion of the young seedlings of winter wheat during spring time 
(Klun and Robinson, 1969) not light which triggers the reproductive cycle of the vok 
6-MBOA, a chemical derived from a component of winter wheat has been reported to be responsible 
for the gonadal stimulation (Sanders et. aI., 1981). 6-MBOA does not only increase the rate of sexual 
maturation in the vole Microtus montanus, but in other species as well, such as the rabbit (Rex), 
kangaroo rat (Dipodomys ordii) (Rowsemitt, 1984) and the albino rat (Butterstein et. aI., 1985). 
There is a similar structural conformation between 5-HT, aMT and NE and this suggests that 6-MBOA 
may be responsible for blockade of aMT gonadal activity inhibition. 
One of the routes of6-MBOA action on gonadal function is through interference withpMT synthesis 
in the pineal gland, 6-MBOA antagonism ofaMT receptors that control gonadal function or direct 6-
MBOA inhibition of gonadal function. The structural similarity between 6-MBOA and NE suggests 
a possibility that 6-MBOA might act as a receptor antagonist and thus prevent catecholaminergic 
stimulation ofNAT, a regulatory enzyme in aMT synthesis. Furthermore, structural similarity between 
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5-HT and 6-MBOA could lead to competition of 6-MBOA with 5-HT for the active site on NAT. 
Both possibilities would lead to decreased synthesis of aMT, an antigonadotropic hormone. 
The antigonadal effects of aMT have been correlated with decreases in follicle stimulating hormone 
(FSH) and luteunising hormone (LH) in the rat (Martin et. al., 1980; Lang et. al., 1983). NE is a 
positive regulator at these sites so the binding of aMT to adrenoreceptors supports the speculation that 
it may compete directly with NE. If this is true, 6-MBOA reproductive effects could be due to its 
ability to antagonize these antigonadal effects of aMT. 
It has been estimated that field grass in early spring contains about 100 - 200 Ilg of 6-MBOA / g wet 
weight and Sanders et. al. (1981) have shown that this concentration of 6-MBOA in the laboratory 
food promotes gonadal growth in young voles weighing 25 g and consuming 5 g of chow per day. This 
dose has been shown to stimulate gonadal growth in the mouse. Yuwiler and Winters (1985) assumed 
that 6-MBOA may also influence synthesis of other pineal indoles. 
1.4.3 Effect of 6-MBOA on pineal function 
a l and a2 of the adrenergic system enhance the production of aMT. NE released by postganglionic 
nerve terminals within the pineal gland acts on a-adrenoreceptors on the pineolocyte membrane to 
increase cAMP production thus enhancing the activity of NAT and aMT concentration subsequently. 
6-MBOA has been shown to influence this pathway and its effects will be reviewed below. 
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1.4.3.1 Effect of 6-MBOA on 6- adrenoreceptor binding and cyclic AMP (cAMP) 
Adenylate cyclase activity is stimulated in tissues innervated by sympathetic fibers including the pineal 
gland after 6-MBOA supplementation (Sweat and Berger, 1988). 10 11M 6-MBOA has been shown 
to be as potent as 1 f..lM isoproterenol in stimulating adenylate cyclase activity (Sweat and Berger. 
1988). 
Yuwiler and Winters in 1985 suggested that 6-MBOA stimulates 13-adrenoreceptors in the same 
manner as does NE and this induction is blocked by a 13-adrenoreceptor antagonist, propanolol. The 
property of 6-MBOA as the 13-adrenergic agonist is shown by its stimulation of adenyl ate cyclases 
from the pineals and other tissues. Furthermore, aMT, a 6-MBOA analogue (Sweat et. al., 1988) binds 
to 13-receptors like 6-MBOA (Sweat et. al., 1986a,b). However, unlike 6-MBOA, aMT does not 
stimulate adenylate cyclase in vitro, but it does decrease the effects of 13-adrenergic agonists (Sweat 
et. al., 1987). 
~ 
Yuwiler and Winters in 1985 reported unexpected findings that 6-MBOA is a weak inducer of NAT 
,I 
activity at relatively high concentrations of 0.92 mM or more. Moreover, they showed that 6-MBOA 
stimulated NAT activity postsynaptically. These authors observed no alteration in subsequent steps 
in aMT biosynthesis. This was evidenced by the fact that pineals exposed to 6-MBOA converted more 
radioactive tryptophan to NAS and aMT as compared to controls in vitro (Yuwiler and Winters, 
1985). It also appeared that 6-MBOA has very weak affinity for the receptor site and is easily 
displaced from it by other 13 1 a.8onists, NE in particular (Yuwiler and Winters, 1985). 
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1.4.3.2 Effect of 6-MBOA on pineal NAT and HIOMT activities 
Yuwiler and Winters (1985) reported that 6-MBOA is a postsynaptic weak inducer of NAT activity 
at concentrations of 0.02 mM and above. Stimulation of NAT is reported to be cAMP dependent and 
the stimulation of NAT was expected to occur at 10-5 since cAMP is increased at such concentrations 
by 6-MBOA, however, Daya et. al., (1990) observed stimulation at 1 mM. Parallel observations on 
NAT induction were reported by Yuwiler and Winters (1985). 
HIOMT activity appears to be unaltered by 6-MBOA regardless of concentrations used (Yuwiler and 
Winters, 1985; Daya et. ai., 1990). 
1.4.3.3 Effect of 6-MBOA on aMT levels 
aMT production in the pineal gland originates with the of stimulation of J3-adrenoreceptors by NE 
which is cAMP dependent. This is followed by stimulation of NAT resulting in the formation ofaMT. 
J 
Daya and Tandt (1993) showed that 6-MBOA stimulates pineal aMT synthesis with a concomitant rise 
in pineal cAMP. Daya et. al. (1990) reported a significant elevation of pineal aMT at concentrations 
of 1 mM and above of 6-MBOA which is in accordance with the concentration required to stimulate 
NAT activity, a regulatory enzyme in aMT biosynthesis. Lower concentrations appear to have no 
effect on both pineal enzymes and on aMT production. 
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1.5 ANTIDEPRESSANTS 
1.5.1 TRYPTOPHAN AS AN ANTIDEPRESSANT 
Rubin (1967) found that the reduced levels of indoleamines in depression is caused by an increase in 
TDO activity which is followed by raised levels of plasma glucocorticoids. These observations were 
confirmed by tracer experiments done by Weil-Malherbe (1972) who showed that one of the few 
unequivocal observations in depression is the change in the activity ofTDO which probably accounts, 
at least in part, for some of the changes of indole metabolism and 5-HT biosynthesis. 
The mode of action of antidepressants on TDO- activity is not regulated by glucose or insulin 
respectively. This finding strongly suggests that antidepressants increase brain tryptophan levels by 
increasing tryptophan availability to the brain secondarily to the inhibition of liver TDO activity 
(Badawy and Evans, 1981)' 
Tryptophan has been used for many years as an antidepressant, but its efficacy is limited by its rapid 
,I 
catabolism. The major site of tryptophan catabolism is the kynurenine pathway in the liver and the key 
controlling enzyme is TDO. Consequently, inhibition of TDO should decrease the catabolism of 
systemic tryptophan, increasing its concentration in the blood and in the brain and thereby increasing 
synthesis and subsequent release of 5-HT (Madge et. ai., 1996). 
It is known that brain tryptophan concentration is increased when TDO activity is inhibited by 
allopurinol, glucose, nicotinamide or chronic administration of ethanol (Badawy and Evans, 1981). 
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Coppen et. al. (1963) observed that, tryptophan can be beneficially used with tricyclic antidepressants 
(TCA's) at very low doses, enough to potentiate the action of these antidepressants. Coppen et. al. 
(1967) showed that L-tryp administration to depressives with or without a concomitant treatment with 
monoamine oxidase inhibitors (MAOI) are effective antidepressants. These researchers claimed that 
tryptophan given alone is as effective as electroconvulsive therapy in the treatment of depression. 
Several drugs and vitamins have been given in combination with tryptophan in clinical use because of 
their effects on peripheral tryptophan metabolism. The most common of these is pyridoxine. It is 
usually used as pyridoxal phosphate as a coenzyme in pathways involving tryptophan metabolism. 
Pyridoxine does not have direct influence on tryptophan metabolism, although it may increase 
decarboxylation of tryptophan to tryptamine by aromatic amino acid decarboxylase. This pathway is 
quantitatively minor and would not influence tryptophan levels (Haber et. al., 1981) and inhibition of 
the enzyme amino acid decarboxylase will not increase the availability of t~ptophan in the brain 
(Young et. aI., 1978). However, pyridoxine may increase decarboxylation of5-HTP fo 5-HT in the 
brain. Coppen (1976) supported this hypothesis because this author discovered that antidepressant 
effects of tryptophan did not differ significantly when it was given with or without pyridoxine. The 
administration of pyridoxine and tryptophan helps prevent accumulation of tryptophan metabolites 
such as kynurenine, 3-hydroxykynurenine (3-0H-K) and xanthurenic acid (XA) which may interfere 
with 5-HT synthesis in the brain (Wolf, 1973). 
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1.5.2 L-5-HYDROXYTRYPTOPHAN (L-5-HTP)AS AN ANTIDEPRESSANT 
Over the past 30 years, a thorough investigation on a massive body of psychobiology has shown 5-HT 
deficiency to be the major cause in conditions such as depression, anxiety, suicide, alcoholism, 
migraine headaches, insomnia and obesity. L-5-hydroxytryptophan, an immediate precursor of5-HT 
is thus hypothesised as the preferable antidepressant hence its administration leads to increased 5-HT 
concentration. 
L-5-HTP is extracted from seeds of Griffonia plant. When neurons convert tryptophan to 5-HT, 
neurons first use a vitamin B3-dependent enzyme, tryptophan hydroxylase (TH) to convert tryptophan 
to 5-HTP. A vitamin B6- dependent enzyme, L-5-HTP decarboxylase is then used to convert L-5-HTP 
to 5-HT L-5-HTP can easily cross BBB and is not a substrate for TDO. It is also not incorporated 
into proteins nor is used to make vitamin B3. The enzyme L-amino acid decarboxylase found outside 
the brain has its highest activity in liver kidney and intestinal lining. It converts L-5-HTP into 5-HT 
which cannot cross BBB. Thus, only L-5-HTP is effective to be implemented~o increase brain 5-HT 
levels and consequently used as an antidepressant (South, 1997). 
1.5.3 L-TRYPTOPHAN-KYNURENINE PATHWAY IN DEPRESSION 
The major pathway of tryptophan metabolism is the kynurenine pathway. It is known as the 
"kynurenine shunt" because the pathway initially, tended to be ignored in studies on depression. In 
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depression, kynurenine levels increase slowly and then remain elevated for a long time, because of 
"self-induction" due to activation of TDO by circulating kynurenines (Lapin, 1976). This effect can 
lead to a prolonged hypothesis which results in asthenic depression (Lapin, 1980). 
Xanthurenic acid output in depressed patients is increased as compared to manic and control subjects 
and that leads to a suggestion that this increase is due to an elevated activity ofTDO enzyme (Rubin, 
1967). Mangoni (1974) suggested that the increase is due to decreased activity of pyridoxal phosphate-
dependent kynureninase. This rearcher also showed a decrease in excretion ofN' -methyl-nicotinamide 
and hypothesized it to result from pyridoxal phosphate-dependency of this metabolite perhaps 
secondary to decreased activity of kynureninase. 
Monoaminergic kynurenines are essential for thymoanaleptic (antidepressant) action of antidepressants 
and kynurenines possess largely similar activity in humans. Kynurenines obstruct the effects of 
antidepressants, considering that the concentration ofkynurenines might be increased in depression. 
A study about this interference was done and it was found that after tryptophan treatment (50 mg/kg), 
\ 
manic depressives excreted less kynurenines than controls (Lapin, 1980). In deprepsive patients, 
resistant to therapy, three times more kynurenine was excreted when compared to controls (Lapin, 
1980). Furthermore, L-tryp administration may cause toxicity by producing an accumulation of 
products in the kynurenine pathway or simply by overloading the liver with ammonium ion since 
tryptophan induces TDO which may inhibit 5-HT synthesis which in turn may inhibit the effectiveness 
of tryptophan on depression (Van Praag and Korf, 1971c). 
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1.5.4 SELECTIVE SEROTONIN REUPTAKE INHmITORS (SSRI's) 
The leading antidepressants are selective 5-HT reuptake inhibitors (SSRI). By blocking the reuptake 
of 5-HT, SSRI increase the 5-HT available to stimulate 5-HT receptors. While SSRI's may be very 
effective for the treatment of depression, these drugs do have side effects e.g. loss of sex drive. SSRI's 
are also expensive and only available by prescription (http://vv'\.\l\v.virtuvites.com!5-htplOOmg.htm). 
The most studied and widely used SSRI is fluoxetine (Klipin, 1998). 
SSRI's have high affinity for 5-HT transport site and low affinity for other NT receptors in vitro. The 
maj ority of these S SRI's are metabolised by N -demethylation. Fluoxetine and its metabolite, 
norfluoxetine are potent SSRI's both in vitro and in vivo (Wong et. al., 1975a). These drugs have 
many adverse side effects. Fluoxetine and norfluoxetine have very few if any anticholinergic side 
effects commonly caused by tricyclic antidepressants (TeA's). Moreover, postural hypotension and 
weight gain have not been reported in these drugs. However, SSRI's have been associated with an 
increased frequency of gastrointestinal side effects including nausea, vomiting,\ abdominal cramps and 
diarrhoea and effects such as restlessness, insomnia, anxiety. These side effects have been shown to 
decrease as treatment continues or with a certain dosage for a particular individual (Lemberger et. aI., 
1985, Mendels, 1987 and Burrows et. al., 1988). 
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1.5.5 TRICYCLIC ANTIDEPRESSANTS 
The clinical efficacy of tricyclic antidepressants has been related to the ability of these drugs to inhibit 
active reuptake ofNE. The therapeutic effect of imipramine discovered in 1958 by Kuhn led to the 
development of a number of tricyclic compounds with antidepressant properties. Chronic and or acute 
administration of tricyclic antidepressants was shown to inhibit total activity of TDO. The 
antidepressants used were, amitriptyline, clomipramine, imipramine or tranylcypromine. Acute doses 
of imipramine can also increase pineal aMT production possibly by direct adrenergic stimulation (Wirz-
Justice et. a/., 1980). Conversely, repeated imipramine injections lead to a decrease in pineal 
adrenergic sensitivity (Moyer et. al., 1981). 
TCA's have adverse side effects. TCA's are also associated with cardiovascular effects such as 
tachycardia and occasional heart block which have been mainly reported in overdosed patients. 
1.5.6 MONOAMINE OXIDASE INHmITORS (MAOI) ANTIDEPRESSANTS 
I 
There is an important link between the metabolism of monoamines and human disorders. MAOI inhibit 
the catabolism of monomanines thus augmenting the levels of monoamines in the sypnaptic cleft. In 
1965, Bunney and coworkers observed that there is a high excretion of 17-hydroxycorticosteroids in 
urine of depressed patients with a high risk of suicide thus suggesting a decreased MAO activity. To 
support this report, Buchsbaum and coworkers in 1976 showed a low MAO activity in blood platelets 
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of suicidal people. Low brain MAO activity has also been discovered in alcoholic suicides. Wyatt et. 
al. (1973b) demonstrated a low platelet MAO activity in some individuals with a high susceptibility 
to schizophrenia. All these reports show that MAO inhibition is definitely associated directly or 
indirectly with psychiatric disorders and is beneficiary in the treatment of these disorders. 
MAOI's were the first clinically effective antidepressants, but their use is now limited because oftheir 
side effects. MAO-A inhibitors interact with sympathomimetic drugs and with tyramine, commonly 
found in cheese ("cheese reaction"). This has limited the use of MAO-A inhibitors in treatment of 
depression. MAO-B does not undergo this interaction and it was thus thought as a more preferable 
antidepressant (Quitkin et. ai., 1984b), but this hypothesis was proven wrong when MAO-B inhibitors 
were found to be effective only at high doses and MAOI-B are likely to lose their specificity at such 
doses (Sunderland et. aI., 1985). Amore preferable MAO-A inhibitor is clorgyline. Clorgyline has been 
shown to have mild side effects as compared to TCA's (Murphyet. ai., 1987a) even at low doses in 
patients with bipolar affective disorders (Robinson et. ai., 1985). 
1.5.7 MELATONIN (aMT) AS AN ANTIDEPRESSANT ,I 
Pineal function and its main hormonal output has been ignored by many clinicians. In the last three 
decades, tremendous developments in the understanding of biochemistry and physiology of the pineal 
gland have occurred. Up to date, it is evidently shown by many researchers that the pineal gland 
interacts with many endocrine as well as non-endocrine tissues to influence their metabolic activity. 
The most studied modulation of organs and their functions by pineal aMT has been done on 
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neuroendocrine -reproductive axis. More research is still to be elucidated on neuroendocrine function 
on psychiatric disorders. 
Low nocturnal aMT has been suggested to be a trait marker for major depressive illnesses and 
depressive states with abnormalities in the hypothalamic pituatory adrenal axis (Beck-Friss et. al., 
1985). In rodents and humans, depression treated with antidepressants such as monoamine oxidase 
inhibitors (MAOI) increases the pineal content ofaMT precursors 5-HT, NAS and aMT respectively 
in both blood and CSF by enhancing NAT activity. However, tricyclic antidepressants reduce aMT 
production and secretion in rodents. Other psychotic drugs that disturb monoamine pathway also 
affect the stimulatory action of adrenergic system and yet reduce aMT production (Lewis et. aI., 1990). 
Lewis et. al. (1990) has reported a link between diurnal and seasonal rhythmicity ofaMT production 
and seasonal affective disorders and various types of endogenous depression. The persistent winter 
depression known as seasonal affective disorder, also characterised by weight gain, carbohydrate 
craving and hypersomnia was found to improve significantly after treatment with bright light 
\ 
(Rosenthal et. al., 1984). It was clearly shown that the inhibitory effect of bJight light on 
pharmacological suppression of aMT does not improve their depression. Therefore light itself is the 
prerequisite to reduce winter depression (Rosenthal et. al., 1986). 
aMT has been shown to be reduced in depressed patients. An increase in the cortiso1:aMT ratio 
together with inverse correlation between aMT and cortisol rhythms have been reported to exist 
indepressed individuals (Claustrat et. al., 1984). However in non-affective disorders such as chronic 
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schizophrenia, abnormally low levels of aMT have been observed (Ferrier, 1993). 
l.6SUMMARY 
Tryptophan is an essential amino acid. It is a precursor of biogenic amines 5-HT and aMTwhich are 
known to play important roles in affective disorders such as depression. 98 % of circulating tryptophan 
is oxidised by the liver enzyme, TDO and only about 1 % or less of the remaining tryptophan goes to 
the brain for the biosynthesis of 5-HT. TDO is induced by glucocorticoids, tryptophan and haem. It 
is inhibited by aMT and 5-HT both in vitro and in vivo. Reduced levels of5-HT and to a lesser extent, 
aMT, are reported to exist in depression, hence TDO is the key regulatory factor in therapeutic effect 
~"'" 
of depression as the enzyme limits the bioavailability tryptophan. 6-MBOA, a plant alkaloid is an 
analogue of 5-HT and aMT. 6-MBOA is reported to increase aMT levels in vitro by inducing NAT 
and adenylate cyclase activity and by acting as a weak p-adrenoreceptor agonist. Drugs which enhance 
5-HT and aMT levels are imperative in treatment of depression. These drugs include MAOI, SSRI's, 
tryptophan, 5-HTP, 5-HT and aMT supplements. 
., 
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EFFECT OF 6-METHOXY-2-BENZOXAZOLINONE 
(6-MBOA) ON HEPATIC TRYPTOPHAN 
2,3-DIOXYGENASE (TDO) ACTIVITY 
2.1 INTRODUCTION 
Tryptophan 2,3-dioxygenase (Ee 1.13.1 1. 1l,TDO) is a haem-dependent hepatic enzyme that 
catalyses the conversion ofits substrate, L-tryptophan (L-tryp) into N' -formylkynurenine. It does 
this by incorporating two atoms of molecular oxygen (02) into L-tryp. TDO exists in two forms 
in the rat and human livers whereas only one form exist in other animals. One\ form exists in an 
.I 
active state (holoenzyme) and the other form requires exogenous haem for its activation 
(apoenzyme). Activation of the apoenzyme in vitro involves its conjugation with haem to form 
the oxidised (ferrihaem) holoenzyme which is then reduced to an active holoenzyme in the 
presence of tryptophan (Badawy and Evans, 1975; Uchida et.al. 1992). 
TDO activity can be regulated by glucocorticoids and tryptophan. Glucocorticoids induce TDO 
activity by causing synthesis of new apoenzyme whereas the substrate tryptophan causes the 
decreased degradation of pre-e?ci~ting apoenzyme dUTing the normal rate of synthesis (Badawy 
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and Evans, 1973). 
It has been shown that haem, a TDO cofactor may also act as a regulating agent in TDO activity. 
Addition of exogenous haem or haem precursors leads to induction of conjugation of the 
apoenzyme with haem and reduction of oxidised holoenzyme to an active form (ferrihaem). In 
contrast, addition of substances which inhibit haem synthesis cause opposite effects (Badawy and 
Evans, 1975). 
Many antidepressants inhibit TDO activity both in vitro and in vivo. Antidepressants have been 
shown to inhibit total but not holoenzyme activity i.e. apoenzyme activity. The fact that these 
drugs exert a direct inhibitory effect on TDO activity in vitro suggests that the apoenzyme 
synthesis is not affected by these drugs but inhibition might be caused by interferance in haem 
saturation ofthe apoenzyme and therefore depends on the endogeneous liver haem content. This 
could be true since haem is dissociable from the apoenzyme (Badawy and Evans, 1981). 
,I 
This study is aimed at investigating the effect of6-MBOA on TDO activity in vivo. 6-MBOA is 
a tryptophan metabolite and aMT and 5-HT analogue. It has been shown that both aMT and 5-HT 
inhibit hepatic TDO activity, It has also been shown in our laboratory that 6-MBOA inhibits the 
enzyme activity in vitro. 
The assay employed in determination of TDO activity in this study was performed as described 
by Badawy and Evans, 1973, 1975 and 1981. Both the holo- and. the apoenzyme activities were 
measured. The apoenzyme actiyi!y was taken as the ~ifference betweenthe total activity (added 
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exogeneous haem) and holoenzyme activity (no haem added). The activities were expressed as 
the nmoles ofL-kynurenine formed per milligram of protein. The absorbance was read at 365nm 
with an extinction coefficient of 4540 Llmo1.cm. 
2.2 ANIMALS AND INJECTIONS 
Male Wistar rats of the albino strain (200-250g) were used for all the experiments. The animals 
were housed in groups of5 (n=5) in opaque rectangular cages with metal floors and covers. Water 
and Epol food were supplied ad libitum. The animal room was windowless and the temperature 
of the room was regulated at 22-25 0 C. The room was artificially lighted and lights were 
automatically regulated to maintain a 12 hr dark (18:00-06:00) and 12 hr light (06:00-18:00) 
cycle. The intensity of the illumination was 300 ,uWatts/cm2. The animals were killed swiftly by 
cervical dislocation and rapidly decapitated. For experiments conducted during the photo-phase, 
animals were sacrificed between 12hOO and 13hOO and for the scoto-phase experiments, animals 
were sacrificed between OOhOO and 01hOO under a dim red light (60 Watts). 
2.2.1 ADMINISTRATION OF 6-MBOA TO RATS 
For all the in vivo studies, the route used for injections was intraperitoneal (i.p). Controls were 
injected with 0.9 % NaCl in 50 % EtOH and the treated animals injected with 10 mg I kg 6-
MBOA dissolved in vehicle. Anplals were injected twice at one hour interval and sacrificed one 
_-hour after the last injection by cervical dislocation. For the photo-phase experiments, the injections 
were initiated between IOhOO and 11hOO and animalS' were sacrificed between 12:00 and 13 :00. 
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For the scoto-phase experiments, injections were initiated between 22hOO and 23hOO and the 
animals were sacrificed between 00:00 and 01:00 under a dim red light (60 Watts). 
For the removal of livers, a mid-ventral incision was made through the abdominal musculature 
from the pelvic region to the posterior edge of the sternum. A transverse cut was made anteriorly 
to expose the liver. A careful removal of livers was done and the livers were dissected free of 
blood vessels and connective tissue. The livers were excised and perfused with cold 0.9 % NaCl 
to remove blood haem that can interfere with conjugation of exogenous haem with apoenzyme. 
Livers were either homogenised immediately after perfusion or immediately stored in liquid 
nitrogen and kept frozen at -70°C until required. 
2.3 CHEMICALS AND REAGENTS 
2.3.1 CHEMICALS 
All chemicals were ofthe highest purity avail~ble. Potassium chloride (KCI), Phosphate buffer, 
Copper sulphate (CuS04'SH20), Sodium tartrate, Sodium carbonate (N~C03)' Folin-Ciocalteu 
(F.C) reagent, Sodium hydroxide (NaOH) and Trichloroacetic acid (TCA) were all purchased 
from SaarchemLimited, Krugersdorp, South Africa. Sodium chloride was purchased from Holpro 
Analytical Division, Midrand, South Africa. Haematin chloride, 6-Methoxybenzoxazolinone (6-
MBOA) and L-Tryptophan (L-tryp) were purchased from Sigma Chemical Co., St Louis, USA. 
__ Ethanol (Abs) was obtained from Chemistry Dept., Rhodes University, South Africa. 
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2.3.2 REAGENTS 
Milli RlQ System, Millipore water (deionised water) was used for preparing all the solutions. L-
tryp (0.03 M) was prepared in 4 mM NaOHjust prior to the start of the experiment. TCA (0.9 
M) and NaOH (0.6 M) was dissolved in deionised water. Sodium phosphate buffer (0.2 M, pH 
7.4) and 0.14 M KCI - 2.5 mM N aOH were prepared in deionised water and refrigerated until use. 
Haematin chloride, final concentration 2 ,UM was freshly prepared in 0.1 M NaOH just before 
commencing with the experiment. 
2.4 HOMOGENATE PREPARATION 
The liver was either used immediately after removal or stored at -70°C as described in section 
2.1.3. The frozen liver was slowly thawed and dried with a paper towel to remove any excess 
water that might interfere with the weight of the liver. The liver was then weighed and 
\ 
homogenized in a mixture of 10 % w/v 0.2 M sodium phosphate buffer, pH 7.4 and 10 % w/v 
I 
0.14 M KCI - 2.5 mM NaOH. HomogenisatiQn was done in a Waring blender for a period of 1 
minute at 1000 rpm. The homogenate was sonicated to free the enzyme from the cells. Sonication 
was done for a period of two minutes at 30 second intervals. All the above steps were done on 
ice sinceboth the blending and especially sonication are exothermic and could lead to reduction 
in enzyme activity. 
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2.5 DETERMINATION OF TDO ACTIVITY 
Table 2.1 below summarises the procedure for TDO assay. The samples containing 10 % w/v 
homogenate (15 ml) were added to 12.5 ml distilled H20 and the solution was gently swirled. For 
total activity determination, 100 ,ul haematin chloride (final concn 2,uM in 0.1 MNaOH, optimum 
for enzyme activity) was added. Furthermore, 2.5 ml of 0.03 M-L-tryp in 4 mMNaOH was added 
to both total and holoenzyme reactions. The mixtures were gently swirled. Samples of 3 mls of 
the assay mixture were transferred to test tubes. The mixtures were stoppered in an atmosphere 
of carbogen (95 % O2:5 % CO2) and incubated at 37 °c in an orbital shaker for a period of one 
hour. The reaction was terminated by an addition-of2 ml 0.9 M TCA and tubes were further 
shaken at 37 °c for 4 minutes then filtered through Whatman no. 1 filter paper. To a measured 
volume (2.5 ml) of the filtrate, 1.5 ml of 0.6 M NaOH was added and the L-kynurenine formed 
was determined by measuring the E365 using a spectrophotometer with an extinction coefficient 
(e) = 4540 Llmol.cm. 
.I 
2.6 HOMOGENATE PROTEIN DETERMINATION 
The homogenate protein concentration was determined by using the method of Lowry et. 
al.(1951). An aliquot of 0.05 ml of homogenate was added to 0.095 ml of H 20. To this, 6 ml of 
alkaline copper reagent solution prepared by mixing 1 ml of a 1 % CuSO 4' 5H20 solution, 1 ml of 
a 2 % sodium tartrate solution and 98 ml of2 % N~C03 in 0.1 N NaOH in order. The mixtures 
- . were vortexed and left to stand at room temperature for 10 minutes. Following that, 0.3 ml of 
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Folin-Ciocalteau (F.C) reagent was added to each of the tubes and left to stand at room 
temperature for 30 minutes in the dark. After incubation, the absorbance was measured at 500 nm. 
Protein standards containing 0 - 150 fJg / ml of bovine serum albumin (BSA) were assayed as 
above and the procedure is summarised in Table 2.2. A typical standard curve obtained is shown 
in fig. 2.1 
Table 2.1 Summary for determination of TDO activity 
I Reagents I Volume (ml) I 
Distilled H2O 12.5 
-
Homogenate 15 
Haematin 0.1 (Total activity) 
L-Tryptophan 2.5 
Transfer 3 ruPio glas~ testtub~st bu~ble· the mixture with carbogen and. iricubate @ 
37 JJC ina rotarvshaker far I hOur .... 
Terminate with 2 ml 0.9M TCA and incubate for a further 4 \nin 
,I 
.... . ... 
., ~ 
FUterlhrough no.lWhatmanfilterpaper 
. ........ .:. .:: .. . ... . 
I 
To 2.5 ml filtrate add 1.5 ml 0.6M NaOH 
I 
..... . 
Vortex. and readAbsat 365nm 
(Blank :l:.ml O.9MTCA + 1~5 ml 0.6MNaOH) 
-
-
". .>. .... 
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Table 2.2 Protein determination using Folin-Lowry method: 
BSA stock solution = 300 J-lg / ml 
.. ... ... 
Concentra.tion V (}Iume prQtein VolumeHzO Alk.Cu. reagent 
I 
(pg/ml) (lIlt) (ml) :: (mIl 
0 0 1 6 
25 0.025 0.975 6 
50 0.075 0.95 6 
100 0.1 0.925 6 
150 0.15 0.85 6 
Stand for 10 min. at rOQm temperatureafte~ addition of prQtein,waterllnd AllLCu 
reagent. 
. ... 
Ad.d 0.3 Il1rF.C''',3gentipJo ea~"tubea.nd le~ve atroomt~mperaturefor 30 min. 
....•....... .... ···_...:Readabsorbance ai365 Rnl .> 
2.7 RESULTS 
I 
Absorbance readings from the triplicate determinants were pooled and averaged. The 
concentration ofL-kynurenine was calculated by applying Beer-Lambert Law and measuring the 
increase in absorbance at 365 nm. 
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2.7.1 Statistical analysis 
All results were analysed by one-way analysis of variance (ANOVA). Statistical differences 
between groups were determined using the Student t-test. Values ofP < 0.05 were taken as 
statistically significant. For determination of post tests, the Bonferroni multiple range test was 
employed. 
2.7.2 Time-course ofTDO activity 
Enzyme activity was measured either in the presence (total enzyme) or in the absence 
(holoenzyme)of haematin and the difference between the two (apoenzyme) showed a time-
dependency profile (fig. 2.2). For the apoenzyme activity, a linear increase was observed from 
T 15 - T 60 which remained constant from T 60 - T 90' The enzyme was induced from T 90 - T 105. The 
other two activities, the total and the holoenzyme appeared to show a linear increase from To -
T 60' From T 60 it followed the same trend as the apoenzyme. One hour incubatioh period was thus 
, 
used for all other experiments. 
2.7.3 Effect of circadian rhythm on TDO activity 
The total and holoenzyme activities appeared not be influenced by light-dark variations, however, 
the apoenzyme activity was significantly altered by these variations (P < 0.05) as shown in fig. 2.3 
_ wi~h higher activity occurring during the photo-phase. 
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2.7.4 Sensitivity ofTDO to 6-MBOA treatment 
The sensitivity ofTDO to 6-"MBOA is shown in fig. 2.4 and fig. 2.5. In both photo- and scoto-
phase samples, 6-"MBOA caused a significant inhibition of apoenzyme activity and it was more 
effective during the photo-phase (P < 0.01 and P < 0.05). Moreover, in photo-phase, 6-"MBOA 
did not only alter apoenzyme activity, the total enzyme activity was also significantly reduced (P 
< 0.001). In contrary to this, holoenzyme activity was not altered by 6-"MBO A in both phases. The 
ratio of apoenzyme / holoenzyme activity indicates the magnitude of conjugation of the enzyme 
with haem and it was found to be more than 1 in both the control and 6-"MBOA treated photo-
phase samples (2.25; 1.25). In scoto-phase samples this ratio was found to be less than 1 (098; 
0.41). In both phases the ratio for treated animals is more or less twice the ratio for untreated 
animals. 
2.8 DISCUSSION 
I 
In the rat, TDO activity is subjected to circardian rhythm. TDO activity demonstrates a diurnal 
oscillation from 09hOO-18hOO with the highest activity observed during the pre-dark period and 
the lowest activity towards the end of the dark period. This hypothesis is reinforced by the results 
obtained from this study (fig.2.3),which showed a significant augmentation in apoenzyme activity 
during the photo-phase (12hOO-13hOO) as compared to the scoto-phase (OOhOO-OlhOO). The 
_ . i~creased TDO activity could be attributable to the de novo enzyme synthesis. TDO synthesis is 
initiated between 08hOO and 09hOO and increases uptil it reaches its maximum at18hOO.Readily 
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Figure 2.1 Protein standard curve using bovine serum albumin (BSA) 
[Data points represent mean of triplicate determinants (r = 0.997)] 
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Figure 2.2 Time-course ofTDO activity in the presence (total enzyme) and the absence 
(holoenzyme) of haem and the difference between the two (apoenzyme). 
Specific activity is expressed as nmoles of L-kynurenine formed per mg protein per min. 
[Data pOints represent mean of triplicate determinants] 
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Figure 2.3 Assessment of light-dark variations of hepatic TDO activity 
[Data represents mean ± SEM; n = 5; ($): P < 0.05; Light- phase: TvsH: P < 0.001; 
Tvsk P < o. 01; HvsA: P < O. 001; Dark - phase: TvsH: P < O. 05; TvsA: P < O. 05; HvsA: P > 
0.05) 
T: Total enzyme activity 
_ H: Holoenzyme activity 
A: Apoenzyme activity 
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Figure 2.4 Determination of the effect of 6-MBOA on hepatic TDO activity: 
Photo-phase samples 
[Data represents mean ± SEM; n = 5; (*): P < 0.01; (#): P < 0.001 TvsH: P < 0.001; TvsA: 
T: Total enzyme activity 
H: Holoenzyme activity 
A: Apoenzyme activity 
P < 0.01; HvsA: P > 0.05 J 
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Figure 2.5 Determination of the effect of 6-MBOA on hepatic TDO activity: 
Scoto - phase samples 
[Data represents mean ± SEM; n = 5; ($): P < 0.05; TvsH: P > 0.05; TvsA: P < 0.01; HvsA: P > 
0.05J 
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Table 2.3 Percentage reduction caused by 6-MBOA on hepatic TDO activity 
Total 63 
Bolo 9.1 
Total 24 
Bolo 
45 
afterl8hOO, enzyme synthesis starts to be reduced. TDO activity thus decreases until synthesis is 
re-initiated (Hard eland and Rensing, 1968). The significant reduction of apoenzyme activity 
during the scoto-phase is in accordance with an inhibitory effect of nocturnal aMT at the level of 
~ 
haem induction (Walsh and Daya, 1997). Total activity showed an insignificant (Student's t-test) 
,I 
reduction during the scoto-phase, however, tpere was a trend towards a substantial increase in 
holoenzyme activity during this period, but non-significant (Student's t-test). The increase in 
holoenzyme activity could suggest that most TDO apoenzyme is not saturated with tryptophan 
during the scoto-phase and thus the apoenzyme remains oxidised. Alternatively, conjugation of 
the apoenzyme with haem is disturbed during this phase which also results to an inactive 
apoenzyme, hence holoenzyme ~ctivity is elevated during this phase. 
TDO is a key enzyme that regulates the availability of tryptophan to the brain since it initiates the 
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catabolism of tryptophan. Tryptophan is crucial for the biosynthesis of biogenic indoleamines 
including the neurotransmitter (NT) 5-HT and aMT which playa vital role in affective disorders 
such as depression. aMT has been shown to be a more specific competitive inhibitor of the liver 
TDO in vitro as compared to other indoleamines (Walsh et. ai, 1994). Preliminary studies done 
in our lab have shown that 6-MBOA, a structural analogue ofaMT that is a more potent inhibitor 
of this enzyme than aMT in vitro. 
In this study, 6-MBOA is shown to cause a significant inhibition of TDO apoenzyme activity in 
vivo with more potency occurring during the photo-phase (figure 2.4 and figure 2.5). No 
significant change was observed in both scoto- ana photo-phase holoenzyme activity, but there 
was an insignificant increase in holoenzyme activity during the scoto-phase as seen in vehicle 
treated animals. The low inhibition of apoenzyme activity by 6-MBOA during the scoto-phase 
could be due to difficulty of 6-MBOA to overcome the increase in basal TDO (holoenzyme) 
activity. 
I 
The possible explanation for this difference could be that since during the scoto-phase the enzyme 
activity is at its minimum, the effect of6-MBOA is thus not as apparent as it is during the photo-
phase. Another possibility could be that 6-MBOA does not have an effect on the enzyme activity 
but other indoleamines such as aMT and 5-HT which have highest production during the dark-
phase and also reported to inhibit the enzyme activity are causatives of this inhibition. TDO 
substrate, L-tryp at high concelltrations is reported to have inhibitory effects on TDO activity. 
- During the scoto-phase, TDO activity is reduced thereby increasing circulating tryptophan which 
can in tum inhibit TDO activiiy:-Another possible mechanism for the smaller reduction in TDO 
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activity in scoto-phase samples may be due to an enhanced holoenzyme activity as explained 
above. 
Two binding sites of the enzyme to the substrate are known to exist. One site is catalytic and the 
other is regulatory (Ishimura et. aI., 1970; Uchida et. ai., 1985). At low substrate concentrations, 
binding takes place only in the catalytic site and with increasing substrate concentrations, 
additional binding can occur at the regulatory site (Ishimura et. a!. , 1970). The NH group is critical 
for the molecule to be capable of acting as a substrate for TDO. NH forms a very strong hydrogen 
bonding (H-bonding) with the acidic amino acid side chain. Conservation of the CHNH2COOH 
in the carbon, is essential for the NH-fastened molecule in the catalytic site to take a configuration 
acquired for the reaction. 
Mode of inhibition in the catalytic-site ofTDO can be exerted in one of the three possible ways. 
Firstly, by binding of the substrate analogue which cannot act as a substrate although it has a 
reactive potential, because it cannot take the correct configuration due to a \lack of functional 
I 
group(s) (RCHNH2COOH) for proper inter~ctions with the protein part of the catalytic site. 
Secondly, the substrate analogue that contains appropriate functional groups and takes a correct 
configuration and is potentially reactive but contains other functional group(s) (OHor CH3) that 
may interact with protein side chain by acting as electron donors, leading to a marked reduction 
in the catalytic ability ofthe haem pocket (Uchida et. ai., 1992). 
_ Fr9m the above insight concerning the catalytic status ofTDO, 6-MBOA appears to qualify as a 
substrate analogue of TDO as iteontains the NH group that is indispensable for the molecule to 
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act as a substrate. However, NH requires the functional group CHNH2COOH for proper 
interactions with the catalytic site to be competent and 6-MBOA lacks that particular group. 6-
MBOA also contains CH3 in position 5 which forms H-bonding with protein side chains that may 
lead to distortion and stiffening of the protein structure in the haem pocket thus leading to 
reduction in flexibility required for the catalysis to occur. Therefore, inhibition ofTDO activity by 
6-MBOA probably occurs via one of the mechanisms discussed above. 
,I 
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3.1 THE EFFECT OF 6-MBOA ON BRAIN SEROTONIN 
(5-HT) LEVELS 
3.1.1 INTRODUCTION 
5-HT is a biogenic amine which was first discovered in the intestine (Vialli and Espamer, 1983) 
and has been characterised in the brain for the last five decades. This has prompted intense 
investigation on the physiological roles of5-HT. 5-HT is an intermediate product of tryptophan 
metabolism and the rate limiting enzyme is tryptophan hydroxylase (TH). 5-HT is primarily 
located in the enterochromaffin cells of the intestine, serotonergic neurons in the brain, platelets 
\ 
of the blood, and in the CSF. Central serotonergic neurons have been associJl.ted with 
physiological functions such as sleep, endocrin'e regulation and cardiovascular control. Most 5-HT 
that is found in circulating blood is concentrated in platelets (http://wVI\.v.ffiL-Hamburg.com). 
The concentration of 5-HT is decreased in brains of subjects with affective disorders such as 
depression (http://www.virtuvites.com). However, pathological conditions such as chronic 
tension, headache, schizophrenia and hypertension are also reported to manifest alterations in 5-
HT concentrations. Therefore, drugs which enhance 5-HT production are very important in 
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treatment of such disorders. Hence this study will evaluate whether 6-MBOA exhibits potential 
antidepressant effects or not. This will be achieved by quantifying brain 5-HT levels before and 
after 6-MBOA treatment. 
In this study, a serotonin-ELISA technique was employed to quantitatively measure brain 5-HT 
levels. The technique is used to measure chemically derivatized serotonin in serum, plasma, urine, 
tissue homogenates and tissue culture supemates. Here, the forebrain tissue homogenate was used 
as the sample. The sample preparation (derivatization) was achieved by dilution of the sample 
followed by incubation of the respective sample with the' Acylation Reagent' . 
Serotonin determination is mainly done by using High Performance Liquid Chromatography 
(HPLC). The reason for choosing Serotonin-ELISA technique is because there are a number of 
difficulties relating to the application ofHPLC method such as pump malfunctioning or column 
blocking. This in tum interferes with the final result and can give broad peaks fVhich are difficult 
to interprete. .1 
The assay procedure conforms to the basic principle of competitive ELISA whereby competition 
between a biotinylated and a non-biotinylated antigen for a fixed number of antibody binding sites 
transpires. The amount ofbiotinylated antigen bound to the antibody is inversely proportional to 
the concentration of the anaylate of the sample. When the system reaches equilibrium, the free 
biotinylated antigen is removed by a washing step and the antibody bound biotinylate4 antigen is 
determined by use of an anti-biotin alkaline phosphatase as a marker and p-nitrophenyl phosphate 
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as a substrate. Unknowns are quantitatively measured by comparing the enzymatic activity of 
unknowns with a response curve prepared by using known standards (http://www.IBL-
Hamburg. com). 
3.1.2 ANIMALS 
Male Wi star rats of the albino strain weighing 200 - 250 g were randomly assembled into two 
groups offive and maintained as described in section 2.2. Administration of6-MBOA to rats was 
done as described in section 2.2.1. Animals were sacrificed between 12hOO and 13hOO. 
F or removal of forebrain, an incision using a pair of scissors was made through the bone from the 
foramen magnum to near to orbit. The top of the skull was lifted with a pair of forceps exposing 
the forebrain for removal with tweezers. Care was taken to remove all adhering tissue and visible 
traces of blood from the forebrain. Immediately after removal, the forebrain was frozen in liquid 
nitrogen and stored at -70°C until required. 
3.1.3 CHEMICALS AND REAGENTS 
3.1.3.1 CHEMICALS 
_ Al] chemicals were purchased from the Research Diagnostics Inc:, Pleasant Hill Rd, Flanders and 
were of the highest purity available. 
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3.1.3.2 REAGENTS 
ASSAY BUFFER: 15 ml of the Assay Buffer Concentrate was diluted 1: 10 with bidistilled 
water up to 150 ml. The buffer was stored at 2 - 8 °C until use. 
WASH BUFFER: 15 ml of the Wash Buffer Concentrate was diluted 1:20 with bidistilled 
water up to 300 ml. The buffer was stored at 2 - 8 °C until use. 
CONTROL SERA: Added 0.5 ml of bid is tilled water to each vial and let stand for 15 
minutes. The mixture was then gently swirled. 
ANTI-BIOTIN-AP: Diluted 60,u1 of the Enzyme Conjugate Concentrate in 6.0 ml of Assay 
Buffer (ready for use). This was prepared freshly prior to use. 
PNPP SUBSTRATE SOLUTION: Dissolved 3 PNPP Substrate Tablets in 8 ml ofPNPP 
Substrate Buffer. The solution was prepared 10 minutes 
prior to use. 
3.1.4 HOMOGENATE PREPARATION 
- . The frozen forebrains were removed from -70°C and thawed. Thereafter, the forehrains were 
dried with a paper towel and weighed. The forebrains were homogenised in 10 % w/v of 0.9 % 
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saline with a glass homogeniser. 20,u1 ofthe homogenate was used for quantification offorebrain 
5-HT. Each sample was done in duplicate. 
3.1.5 SAMPLE PRE PARA TION 
After removal of assay reagents from the refrigerator, reagents were allowed to reach room 
temperature before pipetting. To 20,u1 of10 % w Ivtissue homogenate prepared in 0.9 % saline, 
100 ,ul of Assay Buffer was added. 25 ,ul of Acylation Buffer 1 (3 %) was added to the mixture 
and immediately vortexed. The mixture was then incubated for 15 minutes at 37°C. Following 
incubation, 4 m1 of Assay Buffer was added and the mixture was vortexed and centrifuged in a 
benchtop centrifuge for 10 minutes at 1.500 x g. 
3.1.6 ASSAY PROCEDURE 
To 50 ,ul each of standard and acylated tissue homogenate, 50,u1 of Serotonin-Biotin hnd 50,u1 
Antiserum were added and the plate was carefully shaken. The mixture was incubated for 
overnight at 2 - 8°C. Thereafter, the mixture was washed 3 times with Wash Buffer and 150 ,ul 
of Anti-Biotin-AP was added to it. This was followed by incubation for 120 minutes at room 
temperature on an orbital shaker (200 rpm). After the incubation, the mixture was washed 3 times 
with Wash Buffer followed by an addition of200 ,ul ofPNPP Substrate Solution. The mixture was 
incubated at room temperature lor 60 minutes on an orbital shaker (200 rpm) as before and the 
reaction terminated by an addition of 50 ,ul ofPNPP Stop Solution. The contents Were briefly 
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mixed by gently shaking the plate and the optical density was read at 405 run within 60 minutes 
after termination of the reaction. 
3.1. 7 RESULTS 
The logarithmic concentrations ofthe standards were plotted against their corresponding optical 
densities. Each sample was done in duplicate and the concentrations of the samples were read 
directly from the standard curve by using their average optical density. The sample preparation 
lead to a 207.25 fold dilution, hence the values read from the standard curve had to be corrected 
by being multiplied by 207.25. Furthermore, a 10 fold dilution of tissue homogenate was also 
taken into consideration for calculation of the final concentration of 5-HT. 
Results were analysed by one-way analysis of variance (ANOVA) and the statistical differences 
between the groups were determined using the student t-test. A significant rise in brain 5-HT 
I 
production was observed after 6-MBOA administration (P < 0.05) as shown in figure 3.2. 
3.1.8 DISCUSSION 
The initial step in brain 5-HT biosynthesis involves hydroxylation ofL-tryptophan by the enzyme 
tryptophan hydroxylase (TH), a rate limiting enzyme (Boadle-Biber, 1982). However, the 
_ c~ncentration of tryptophan usually present in neurons that produce 5-HT may not be sufficient 
to saturate TH. Thus, brain serotonin synthesis may< normally be limited by the availability of 
81 
Figure 3.1 
Chapter 3 
0.7 .....----------------------------'-0 
0.6 
eO•5 
c: 
Lt') 
o 
..... @l.4 
f/) 
.c 
« 
0.3 
0.2 
• 
0.1 ~-~-----_;-----r_---;_-----_r----~-~ 
1.041 -1.301 -0.854 -0.398 -0.079 0.568 
log cancn (ng I mg tissue) 
Brain serotonin standard curve using the competitive ELISA technique 
[Each data point represents mean of triplicate determinants, r = O.987} 
82 
Chapter 3 
, 0, 
j UI 
, 
i 
I 
I ? c:; L 
C - j! 
U I q:: -v 
r- I L o/', 
2 Of u Q) :J 
C Ul 
- Ul 
1 51 
c -
0 +' 
+' 
0 OJ I L E -~ 
Q)~ ! I lJ'J OJ I I 
1 O~ I C I c~ I 
- i (\j 
o Sf 
L 
m 
I 
I 
! 
I 
I 
00 1 
~ LJC~ntrol ~ 6-MBOA I 
Figure 3.2 Determination of the effect of6-MBOA on serotonin (5-HT) production 
using the competitive ELISA technique 
[Data represents mean ± SEM: n = 5; ($): P < 0.05] 
83 
Chapter 3 
tryptophan. (Mckean et. al., 1967). A variety of drugs and treatments thought to accelerate brain 
5-HT biosynthesis have been shown by many researchers to induce parallel changes in brain 
tryptophan content. Hence, any drug which increases tryptophan availability to the brain is 
essential for the biosynthesis of 5-HT. 
6-MBOA, a structural analogue of 5-HT has been shown in this study to augment brain 5-HT 
levels. An increase in 5-HT biosynthesis could be due to an increase in tryptophan availability 
which can result to stimulation of TH. Another possible explanation could be that 6-MBOA 
stimulates the release of stored 5-HT within nerve terminals into the synapse. 
3.2 THE EFFECT OF 6-MBOA ON TRYPTOPHAN 
HYDROXYLASE (TH) ACTIVITY 
.1 
3.2.1 INTRODUCTION 
Having established that 6-MBOA enhances 5-HT production, it was necessary to investigate 
whether the effect was in par with the stimulation of TH, a rate limiting enzyme in 5-HT 
biosynthesis. Furthermore, a limiting factor in 5-HT biosynthesis is the bioavailability of 
tryptophan and TH is usuall¥ not saturated with tryptophan, which is its substrate. But 
-
- . interestingly, the previous study has shown that 6-MBOA inhibits hepatic TDO activity thus 
leading to a rise in tryptophan available to the brain, therefore this lead to a more positive 
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apprehension for stimulation of the enzyme. 
Tryptophan hydroxylase, a brain mono oxygenase catalyses the rate limiting reaction in the 
synthesis of 5-hydroxy-indoles, including 5-HT. 
The substrate for this enzyme is L-tryp and the natural cofactor is tetrahydrobiopterine (BH4). 
However, there are some aspects which affect the enzyme activity and one ofthem is the diurnal 
rhythm of circulating L-tryp and 5-HT. It has been suggested that an average of 5 J..lg / g of brain 
content ofthe amino acid is obtained but higher values have also been reported, ranging from 2. 5 -
4.5 X 10-5 M (McKean et. ai., 1968). An accepted km value of3 x 10-4 ML-tryp for both crude 
and partially purified enzymes have been reported (Jequier et. ai., 1969; Ichiyama et. ai., 1970). 
This km is somewhat an incautious conclusion because the km is much higher than the free 
typtophan in the brain thus leaving the enzyme unsaturated. This leads to an intriguing concept 
that tryptophan concentration in the brain may be the limiting factor in the synthesis of 5-HT, but 
in vivo it is clear that TH does not operate under substrate limitation. 
,I 
TH in the brain was first demonstrated by Grahame-Smith in 1964 . Grahame-Smith showed that 
homogenates from the dog and rabbit brain stems hydroxylate L-tryp to produce 5-HTP 
(Grahame-Smith, 1964). Investigations on the partial purification and some properties of the 
monooxygenase rabbit brain stem have been briefly described (Nakamura et. ai., 1965). However, 
the relatively low activity of this enzyme and the lack of sens~tive and convenient assay have 
- . 
hindered further studies on purification and properties of the enzyme as well as the reaction 
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mechanism involved. 
The present study undertaken follows the reaction of the radioactive L-tryp as the substrate for 
the enzyme and tritiated water used as a measure ofTH activity. When 3H-L-tryp is hydroxylated, 
5_3H is replaced by a hydroxyl group. The displaced tritium exchanges with water and one mole 
of tritiated water is formed per mole of5-HTP formed. 
3.2.2 ANIMALS 
Male Wi star rats of the albino strain weighing 200 - 250 g were randomly assembled into two 
groups of five and maintained as described in section 2.2. Injections were done as described in 
section 2.2.1. The animals were sacrificed between 12hOO and 13hOO. 
The forebrains were removed as described in section 3.1.2. Immediately \ after removal of 
I 
forebrains, the brain stems were separated by. a spatula, weighed and homogenised with 20 % 
w/v 0.01 M phosphate buffer. 4 ml of crude enzyme homogenate was used for determination of 
TH activity. Each sample was done in triplicate. 
3.2.3 CHEMICALS 
- . AH chemicals were of the purest quality. DL-5-3H-tryptophan (36 ,£.lei / mmol), L-tryptophan and 
DL-5-hydroxytryptophan (DL-S:HTP) were purchased from Amersham, Life Sciences, England. 
86 
Chapter 3 
3.2.4 CRUDE TH ASSAY PROCEDURE 
0.95 ml ofDL-3H-Tryp - L-Tryp (final concentration of 0.2 mM) was added to 4 ml of crude 
enzyme homogenate. 0.05 DL-5-HTP was then added as 5-HTP decarboxylase inhibitor and the 
mixture was aerated with carbogen (95 % O2 and 5 % CO) and sealed. This step was followed 
by incubation at 37 DC for 1 hour thereafter the reaction was terminated by the addition of3 ml 
ono % TCA. The tubes were then left to stand at room temperature for 1 hour to allow complete 
extraction of product. Tritiated H20 was removed by distillation. To 1 ml of distillate, 3 ml of 
scintillation fluid was then added to 3H20 and tpe radioactivity was counted in a LS-2800 
Beckmann scintillation counter. 
3.2.5 RESULTS 
~ 
The results for determination of TH activity were expressed as dpm' s 3H20 I ml distillate . 
.I 
Statistical difference between the two groups. was determined by use of Student's t-test. Figure 
3.3 indicates a significant increase (P < 0.05) in TH activity effectuated by in vivo administration 
of6-MBOA. 
3.2.6 DISCUSSION 
-
- . TH a rate limiting enzyme in 5-HT biosynthesis utilises tryptophan as a substrate(Reiter, 
1980).Para-chlorophenylalanine(PCPA), a powerfUl depletor of tissue 5-HT in vivo appears to 
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Figure 3.3 Determination of the effect of 6-MBOA on brain-stem TH activity 
[Data represents mean ± SEM; n = 5; ($): P < 0.05] 
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be a potent inhibitor ofTH (Reiter, 1989). 6-MBOA on the other hand appears to enhance TH 
activity. The crucial prerequisite for TH catalytic activity is suggestive to be the amino group that 
contains no bulky side chain that may lead to distortion or reduction of the catalytic activity ofthe 
enzyme as is the structure of PCP A. It can thus be suggested that 6-MBOA might enhance TH 
activity by acting as a substrate for the enzyme. Alternatively, the increased bioavalability of 
tryptophan caused by inhibition of hepatic TDO activity by 6-MBOA might lead to the saturation 
of the enzyme and consequently enhancing the enzyme activity. 
3.3 DETERMINATION OF THE EFFECT OF 
6-MBOA ON BINDING OF RADIOACTIVE 
SEROTONIN ON SYNAPTOSOMAL MEMBRANE 
3.3.1 INTRODUCTION 
Brain cells communicate with each other by sending NT's to each other. The NT is released from 
the nerve terminals located at the end of the axons. After diffusing across the synapse, the NT 
binds a receptor located on the surface of the post-synaptic cell. Binding of NT to receptor 
induces, inhibits or modulates currents of ions across the cell membrane (South, 1997). 
Human mood disorders such as_depression are effe9tively treated with drugs which specifically 
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block the reuptake of 5-HT (a NT essential in the treatment of depression) into the presynaptic 
axon terminal. 5-HT is synthesized within the nerve cell from tryptophan. When 5-HT is 
synthesized, it can be stored within the presynaptic or membrane vesicles within the nerve 
terminals. Most of the released 5-HT is reabsorbed by the nerve terminals for repackaging and 
reuse. The re-uptake site (carrier or transporter), a specialised proteinaceous structure located in 
the nerve terminal membrane is responsible for this process. 5-HT uptake sites can be quantified 
by either measuring the rate of the uptake itself or by binding of radioactively labelled ligands that 
bind specifically to the uptake carrier and subsequently measuring the radioactivity 
(http://v.lvvw.ecstasv.org!leon.html). 
An important aspect ofthe membrane preparation is to be able to obtain high density binding sites 
and eliminate a large portion of endogenous contaminants which may interfere with the assay. 
Subcellular fractionation techniques are often designed to isolate synaptic membrane based on one 
or two morphological or biochemical criteria. The major drawback for the use Qfthese techniques 
is their inability to isolate the total synaptic membrane fraction. However, the us~ of crude 
preparations leads to relatively high levels of non-specific binding. The choice of a synaptic 
membrane preparation should entail prevention of the loss of membranous fractions thereby 
reducing the extent of non-specific binding. 
In the present study, the technique of binding of radioactive 5 -HT to synaptosomal membrane was 
employed. The procedure for the preparation of cerebral synaptosomal membrane Wcl-S followed 
as described by Foster et. al,.1981, Cotman and Taylor, 1972 and Brose et. al., 1990. This 
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procedure involves the removal of endogenous compounds which interfere with the binding ofthe 
ligand to the membrane. A crucial step in this procedure involves the lysis of synaptosomes and 
membrane vesicles by osmotic or mechanical shock and subsequent washing by repeated 
centrifugations to rid the membrane of any contaminants. The aim of this study was to investigate 
the effect of 6-MBOA on binding of 5-HT to synaptosomal membrane in vivo. 
3.3.2 ANIMALS 
Male Wi star rats of the albino strain weighing 200 - 250 g were randomly assembled in two 
groups offive and maintained as described in section 2.2. Injections were done as described in 
section 2.2.1. The animals were sacrificed between 12hOO and 13hOO. 
The forebrains were removed as described in section 3. 1.2 and immediately frozen in liquid 
nitrogen and kept at -70°C until required. 
3.3.3 CHEMICALS 
All chemicals were ofthe highest purity. Hydroxy-[side-chain-2-14C]tryptamine creatine sulphate 
(56 mCi / mmol) was purchased from Amersham, Life Sciences, England, Sucrose purchased from 
Riedel-deHaen, Trizma and acetate from Sigma Chemical Co., Canada. 
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3.3.4 PREPARATION OF CEREBRAL SYNAPTOSOMAL MEMBRANE 
The forebrains were rapidly removed from the rats after sacrifice as described previously in section 
3.1.2. All the following steps were performed on ice and centrifugations perfomed at 4 DC. The 
forebrains were pooled together and homogenised in ice cold 10 % (w / v) 0.32 M sucrose in a 
glass homogenizer with a Teflon pestle. The homogenate was centrifuged at 1500 x g for 5 
minutes in a Beckman centrifuge with a J A 21 rotor. The supernatant was put aside on ice while 
the pellet was washed by resuspending it in a similar volume of ice cold sucrose and re-
centrifuging as before. The supernatants from botR steps were pooled together and centrifuged 
at 17 000 x g for 10 minutes in a Beckman L8 -80M ultracentrifuge with a 70 Ti rotor. The 
supernatant was discarded while the pellet was resuspended in 20 ml of 200 ,uM tris acetate 
buffer, pH 7.2 and incubated for 15 minutes at 4 DC .. Thereafter, the suspension was centrifuged 
at 50 000 x g for 25 minutes in a Beckman L8 - 80 ultracentrifuge with a 70 Ti rotor. The pellet 
\ 
as recovered and washed four times by resuspending it in 200 ,uM tris acetate buffer, pH 7.2 
,I 
andre-centrifuging as before. The final pellet :vas resuspended in 10 % sucrose and layered onto 
a discontinous sucrose density gradient which consisted of 10 ml of each 0.85 M, 1.0 M and 1.3 
M sucrose. As the centrifuge tubes were made non-wettable polyallomer, the gradient was layered 
by adding the lightest sucrose solution first. The solutions were applied to the apex of the tube and 
the lighter concentration was allowed to float up from the bottom. The gradient was centrifuged 
in a Beckman L8 - 80M ultra~entrifuge with a SW 28 rotor. The synaptic plasma membrane 
- . fraction at the 1.0- 1.3 M sucrose interface was collected, diluted-with 200 ,uM tris acetate buffer, 
pH 7.2 and centrifuged at 50 008- x g for 20 minutes in a Beckman L8 - 80M ultracentrifuge with 
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a 70 Ti rotor. The resulting pellet was resuspended in 50 mM tris acetate buffer, pH 7.2 to give 
a protein concentration of 1 mg I ml. 
3.3.5 PROTEIN DETERMINATION OF CEREBRAL HOMOGENATE 
The protein concentration of the cerebral homogenate was determined by the method of Lowry 
et. al. (1951) as described in section 2.6. 
3.3.6 DETERMINATION OF BINDING OF SEROTONIN ONTO 
SYNAPTOSOMAL MEMBRANE 
The binding procedure is summarized in Table 3.1. The procedure was initiated by addition of 
200 ,Lil aliquots of the prepared cerebral homogenate to tubes containing 40 ,Lil of varying 
~ 
oncentrations of [14C]5_HT (0 - 1 ,LiM) made up to a final volume of 250 ,Lil with 50 mM tris 
J 
acetate buffer, pH 7.2. Non-specific binding was assessed by replacing 10 ,Lil of the tris acetate 
buffer with 10 ,Lil of 2.5 mM cold 5-HT solution. The tubes were incubated at 20°C for 30 
minutes. The incubation was terminated by the addition of 4 ml ice cold buffer. The samples were 
then rapidly filtered through pre-wetted Whatman GF/C glass microfilters in a 12 place Millipore 
sampling manifold. Each filter was washed three times with 4 ml cold buffer. The filters were 
transferred to scintillation via~ containing 3 ml of scintillation fluid and shaken for an hour. 
- Radioactivity was quantified in a Beckman LS 2800 scintillatiori counter. 
93 
Chapter 3 
3.3.7 RESULTS 
The results are expressed as dpm's of specifically bound radioactive 5-HT. Specific binding was 
calculated as the total binding minus the non-specific binding determined in the presence of 2. 5 
rnM cold 5-HT. 10 mg/kg 6-MBOA was shown to have no effect on specific binding of 
radioactive 5-HT on forebrain synaptosomal membrane from 0.1 nM to 10 nM and from 800 nM 
to 1 rnM. An insignificant inhibition of 5-HT specific binding was only shown to occur from 50 
nM up to 600 nM concentration (figure 3.3). 
Table 3.1 Summary for [14C]5_HT Binding Assay 
..... ...... . ....•....... 
REAGENTS • ... NON-Sl-ECIFICBINDING 
(i...... CNTRL . ·6+MBOA CNTltL i< .. 6-MBOA 
Cc 
Buffer (,uI) 10 10 
[14C]5-HT (,uI) 40 40 40 40 
5-HT (,uI) 10 ,10 
Homogenate (,ul) 200 200 200 200 
... 
.. < .... 
Incubate at 20°C for 30 minutes 
Buffer (mI) 4 4 4 4 
...... . .. ... 
FilterthroughWhatl11anGF / eglass fibtxs then wash filtet.s 1 x with 4 .mIke cold buffer 
Scintillation fluid (mI) 3 3 3 3 
..... 
... 
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Figure 3.4 Determination of the effect of 6-MBOA on specific binding of radioactive 
5-HT on cerebral synaptosomal membrane 
[Data represents mean aftriplicate determinants; n = 5] 
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3.3.8 DISCUSSION 
From the results, 6-MBOA is shown to cause an insignificant reduction of binding of5-HT to the 
synaptosomal membrane. Reductions in ligand binding are very difficult to interpret as they may 
be caused by either reduction in nerve terminals as a result of degeneration or by down regulation 
of the uptake transporter. Loss of 5-HT nerve terminals is suggested by the reduction in the 
density of 5-HT uptake carriers as indicated by reduced 5-HT binding of specific 5-HT uptake 
ligands (Battaglia et. ai., 1988). Another possible explanation for the reduction could be that 6-
MBOAis a structural analogue of5-HT so it migh(compete with 5-HT for binding to the carrier 
protein that is responsible for the uptake process. 
Inhibition of 5-HT uptake is very essential in affective disorders hence drugs which specifically 
block the uptake of 5-HT are used for the treatment of depression. However, the resultant 
enhanced 5-HT activation leads to a cascade of reactions which ultimately r~sult in a reduced 
I 
sensitivity of presynaptic autoreceptors for 5-HT synthesis. This suggests a dysregulation of NT 
existence in depressive disorders (http://\V\\''W".csuchico.edu/psylBioPsych!serotonin.html). 
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3.4 DETERMINATION OF THE EFFECT OF 6-MBOA 
ON URINARY 5-HIAA EXCRETION 
3.4.1 INTRODUCTION 
Tryptophan is a dietary precursor of 5-HT and 5-HIAA respectively. 5-HIAA is an essential 
metabolite of 5-HT catabolism. An increase in 5-HIAA in urine (mg) indicates an appreciable 
portion of tryptophan being metabolized via the 5-hydroxyindole route. 5-HIAA excreted in the 
urine may be derived from 5-HTP, an immediate precursor of 5-HT and 5-HT itself. 
Many researchers have reported differences in 5-HIAA concentrations in the CSF of depressed 
and non-depressed subjects. Bulat and Zivkovic (1971) stated that 5-HIAAin the CSF is of spinal 
\ 
cord origin. Curzon et. al. (1980) showed that it is only lumbar CSF from depressed p~tients that 
has lower 5-HIAA levels than the controls, ventricular 5-HIAA values reflect reduced spinal-
neuronal activity which could occur as a result of the motor retardation which commonly occurs 
in depressed patients. However, Asberg et. al. (1976a) observed that there are two groups that 
exist. One group showed decrease in 5-HIAA levels and the other group retained its normal 5-
HIAA levels. The former group was very much more likely to be suicidal than the latter group 
(Asberg et. al., 1976b) and the-latter group was more likely to show an increased tendency to 
-
- . develop some episodes of depression (Van Praag,1976). From these observations, it can be 
concluded that changes in 5-HlAA concentrations may be an indication of some sort of a 
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depression episode. 
The purpose of this study was to determine whether administration of 10 mg/kg of 6-MBOA 
could affect urinary 5-HIAA excretion. This was prompted by the results obtained from the 
previous studies which showed that 5-HT is increased after 6-MBOA administration, because 5-
HIAA is an essential metabolite of 5-HT. 
There are a number of different techniques which are used to quantitavely measure the amounts 
of 5-HIAA in the urine. These techniques include gas chromatography, HPLC and 
spectroflourimetry. All three mentioned techniques require specialised equipment and are 
expensive. A technique used for the estimation of 5-HIAA in this study employed a method 
modified from Udenfriend et. al. (1956). This is a very old and time consuming method but the 
technique is sensitive (mg 5-HIAA obtained), specific and cost effective. The technique involves 
the pretreatment of urine with dinitrophenylhydrazine (DNPH) to react with keto acids that might 
be present in urine. The technique is colorimetric and the keto acids are said to interfe/e with the 
final colour if not removed and that may give false positives in the final results. Most urine samples 
contain a lot of keto acids therefore the precipitate formed (keto acids-DNPH) should be removed 
by centrifugation. The acidic urine is then extracted with chloroform (CHC13) twice. Furthermore, 
5-HIAA is extracted with ether and sodium chloride/ NaCI is used to saturate the aqueous layer 
so that 5-HIAA can be extracted into ether because of the low distribution coefficient of5-HIAA 
between ether and water. Ether extract is returned to neutral pH (pH 7) for colorimetric assay 
because high pH values lead to instability of the compound. Ether is evaporated and the aqueous 
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layer is reacted with nitrosonaphthol and nitrous acid reagent. A colour reaction with this reagent 
(violet chromophore) is characteristic of5-HIAA. More than 20 phenolic compounds including 
tryptamine and some 7 -hydroxyindoles do not respond to this reagent to give the authentic colour. 
5-HIAA is then extracted twice with ethyl acetate and the aqueous phase is transferred to a 
micro cuvette and the absorbance read at 540 nm. 
3.4.2 ANIMALS 
Male Wistar rats of the albino strain weighing 200 - 250 g were used. Tap water and Epol food 
were supplied ad libitum. The temperature and lights of the animal room were maintained as 
described in section 2.2. The route for adminitration of 10 mg/kg 6-MBOA was intraperitoneal 
(i.p.). Two injections initiated between lOhOO and llhOO were given at one hour interval. 
Immediately after the first injection, rats were individually placed in catabolic cages and the urine 
samples were collected for a duration of 24 hours and analysed. 
I 
3.4.3 CHEMICALS AND REAGENTS 
3.4.3.1 CHEMICALS 
Chemicals used were of the highest purity available. The chemicals were purchased from the 
_ . Cl.!emical Store, Rhodes University, South Africa. 
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3.4.3.2 REAGENTS 
1-Nitrosonaphthol reagent was prepared by dissolving l-nitrosonaphthol in 0.1 % absolute 
ethanol, nitrous acid reagent prepared by mixing 2.5 % NaN02 (0.2 ml) and 2N HCI (5 ml) and 
2,4-dinitrophenylhydrazine (2.4-DNPH) was dissolved in 5 % in 2N HC!. 
3.4.4 METHOD FOR THE ESTIMATION OF 5-HIAA IN THE RAT 
URINE USING A COLORIMETRIC ASSAY 
To 1 ml urine, 1 ml2,4-DNPH reagent was added. The mixture was incubated for 30 minutes at 
room temperature and was gently shaken at 10 minutes intervals for complete removal of keto 
acids. 4.2 ml CHCl3 was added and the mixture centrifuged at 3 000 x g for 5 minutes. To an 
aqueous layer, 4.2 ml CHCl3 was added. The mixture was centrifuged at 3000 x g for 5 minutes. 
1.7 ml aqueous layer was added to a test tube containing 0.6 g NaCI and 4.2 ml ether. The mixture 
I 
was vortexed and centrifuged for 5 minutes. 3.3 ml ether aliquot was transferred to a tube 
containing 0.25 ml phosphate buffer, pH 7.0. The mixture was shaken and centrifuged for 5 
minutes at 3000 x g. Ether was evaporated in a fume hood under a gentle stream of nitrogen (N2)' 
0.17 ml of aqueous layer was transferred to a tube containing 0.08 ml nitrosonaphthol reagent. 
Nitrous acid was added to this mixture (0.08 ml). The mixture was vortexed and warmed at 37 
°C for 5 minutes. 0.83 ml ethyl acetate was added and the mixture vortexed to separate the two 
layers. Ethyl acetate was carefully removed and fresh ethyl acetate (0.83 ml) was added and ethyl 
-
acetate was then carefully ryIlloved as before. T<he aqueous layer containing 5-HIAA was 
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transferred to a cuvette and the optical density read at 540 run. The standards of concentrations 
ranging from 10 - 200 ,umoles were treated the same way as urine samples. Water was used to 
replace urine for blanks. 
3.4.5 RESULTS 
The concentration of urinary 5-HIAA was read from the standard curve and converted to ,umoles 
I ml urine. In figure 3.4 it is shown that 6-MBOA significantly increases the urinary excretion of 
5-HIAA (P < 0.001). To determine if the corr~ct metabolite was extracted, a thin layer 
chromatography (TLC) plate of the authentic 5-HIAA and that of the urine extract was run and 
the respective Rf values obtained were 0.27 and 0.26 which shows that an accurate metabolite was 
obtained in the final product. 
3.4.6 DISCUSSION 
5 -HIAA is a normal constituent of mammalian urine. Van Praag et. al. (1973) and Van Praag and 
De Hans (1979) observed that there is a drastic increase in 5-HIAA in depressed patients. An 
increase in 5-HIAA excretion suggests that the major route for tryptophan metabolism is through 
the 5-HT biosynthesis since 5-HIAA is a major metabolite of 5-HT metabolism and is reported 
to be quite stable in urine as compared to other indoleamines. 
6-MBOAhas been shown to srgnificantly increase urinary excretion of5-HIAA(fig.3.4). Shopsin 
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Figure 3.5 5-HIAA standard curve using the colorimetric assay 
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103 
Chapter 3 
et. al. (1972) and Wilk and Green (1973) have shown that a single dose of tryptophan slightly 
increases the amount of 5-HT and this is reflected by increased levels of 5-HIAA, but when 
tryptophan is combined with MAOI or pretreated with MAOI 5-HIAA levels are decreased since 
MAOI block the catabolism of 5-HT to 5-HIAA. From this study it may be proposed that 
increases in urinary excretion of5-HIAA caused by 6-MBOA administration might be due to an 
increase in brain and CSF 5-HT and that in vivo, 6-MBOA does not have any significant effect 
on MAO activity. 
Whereas studies on CSF and urinary metabolites may be indicative of abnormalities in central 
amine neurotransmission, further experiments need to be employed to verify the amine hypothesis 
of depression. 
., 
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4.1 INTER-INDIVIDUAL VARIATION IN NAS AND aMT 
PRODUCTION 
4.1.1 INTRODUCTION 
The levels of aMT have been reported to change in patients suffering from depressive illness 
(Beck-Friss et. aI., 1984). However, studies about the existence ofinter-individual differences 
in the production of this indoleamine has been limited. Lynch et. al. (1975) showed that there 
are two distinct groups ofaMT and NAS producers, the high and the low producers. These 
authors detected this by taking healthy volunteers and measuring each individual's aMT and 
NAS levels. Bergianniki et. al. (1995), made a sequel on this study by measuring the urinary 
excretion patterns among healthy volunteers for a year on a monthly basis. Healthy volunteers 
were used as controls since they showed a clear distinction between these two groups. 
~ 
The aim of this study was to investigate 'whether rats can be divided into these respective 
groups ofNAS and aMT producers and the mean used as the reference point. The activity 
of animals which rate above the mean be regarded as high producers (HP) and the animals " 
below the mean will be rated as low producers (LP) ofNAS and aMT. The animals which 
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have scores that are very close to the mean will be an indication of the existence of the third 
group of animals, which can be called the intermediate group of producers. 
The pineal NAS and aMT levels were determined using the pineal organ culture technique. 
The organ culture technique was discovered in the early 1920' s. It was mainly used for the 
culture of embryonic rudiments. To date, organ culture systems are employed in the study of 
the physiological and biochemical properties of many living tissues. Trowell (1959) developed 
a technique which allowed a number of fully differentiated organs, or parts thereof to remain 
viable in vitro without either growth or dedjfferentiation thus opening a path to many 
experimental studies. 
Pineal organ culture technique is a very sensitive technique. It measures trace quantities of 
indole metabolites ranging from picomole to micromole concentrations. It is also a useful 
technique in that it eliminates the complexities of organ interaction and\ allows for direct 
.I 
pharmacological manipulation. Klein (1969) reported that the rat pineal glands cultured in 
adequately aerated medium and incubated at 37°C tend to stay for at least six days. 
the pineal gland in culture medium is able to utilize an exogenous radioactive precursor 
(tryptophan, 5-HTP and 5-HT) to synthesize different radioactive indoles. It is believed that 
approximately 95 % of the synthesized radioactive indoles are secreted into the culture 
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medium during the incubation period (Klein and Rowe, 1970; Skene, 1985). The radioactive 
indoles are then separated using a bi-dimensional thin-layer-chromatography (Klein and 
Notides, 1969; Daya and Potgieter, 1982). 
G 
MEL 
(j) SECOND DIRECTION 
SlIT / SMI ETHYL ACETATE 
\ 
FIRST DIRECTION(x2) 
CHLOROFORM: METHANOL: GLACIAL ACETIC ACID 
5HT : Serotonin (5-Hydroxytryptamine) 
5MT : 5-Methoxytryptamine 
~~S :~-acetylserotonin 
MEL : Melatonin 
5ID.AA. : 5-Hydroxyindole acetic acid 
5HTOH : 5-Hydroxytryptophol 
5MIAA : 5-Methoxyindole acetic acid 
5MTOH : 5-Methoxytryptophof 
Figure 4.1 A typical bi-dimensional thin-layer chromatogram of the pineal 
indoles (Modified from Klein and N otides, 1969) 
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4.1.2 ANIMALS 
Male Wistar rats ofthe albino strain weighing 200 B 250 g were randomly assembled into test 
groups of five and maintained as described previously in section 2.2. For photo-phase 
experiments, animals were sacrificed between 12hOO and 13hOO and for scoto-phase 
experiments, animals were sacrificed between OOhOO and 01hOO under a dim red light (60 
Watts). 
For removal of pineal gland, the top of the skultwas removed by making an incision through 
the bone on either side of the head from the foramen magnum to near the orbit. The skull was 
lifted with a pair offorceps exposing the pineal gland for removal with tweezers. All adhering 
tissue and visible traces of blood were carefully removed. 
4.1.3 CHEMICALS AND MATERIALS 
BGJB medium (Fitton-Jackson modification) was obtained from GibcoBRL, Life 
Technologies. Absolute alcohol from Chemistry Dept. Rhodes University, South Africa. 
Novopen (600 mg ~ 1 million units) = Sodium Benzylpenicillin B.P., Streptomycin sulphate 
B.P., FungizoneR = AmphoterinB and non-radioactive 5-HT, NAS, aMT, 5-HTOH, 5-IDAA, 
5-MTOH, 5-MIAAandDimethylbenzaldehyde (DMBA) were obtained from SigmaChemi cal 
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Co., St Louis, USA. 5-Hydroxy-[side-chain-2-14C]tryptamine sulphate creatine sulphate (56 
mCi I mmol) was obtained Amersham, Life Sciences. TLC plates (20 x 20 cm silica gel, 
60F 254) were obtained from Merck, Germany. Emulsifier Scintillation Plus was obtained from 
Parkard. Glacial acetic acid was obtained from uniV AR. Chloroform HiPerSolv for HPLC 
and methanol were obtained from BDH Laboratory Suppliers. 
4.1.4 REAGENTS AND METHODOLOGY 
4.1.4.1 PREPARATION OF CULTURE MEDIUM AND REAGENTS 
Culture medium preparation was perfomed under a laminar flow hood with UV utilized as 
the light source for sterilization. 5 g of sodium benzylpenicillin B.P., streptomycin sulphate 
B.P. and amphoterin B were added into the BGJB medium to prevent any bacterial and fungal 
infections that may contaminate the medium. The culture medium was then stored at 4 DC 
until use. 
I 
4.1.4.2 PREPARATION OF UNLABELLED INDOLES FOR TLC 
Of each unlabelled indole, 4 Ilg was dissolved in 1 ml of 95 % ethanol containing 1 mg If ml 
ascorbate (ascorbate was used as an antioxidant). The mixture was kept away from light and 
room exposure to prevent photo-oxidation and thereafter stored at 4 DC until use. 
4.1.4.3 COMPONENTS OF TLC SOLVENTS 
" 
" 
Mobile phase A - chloroform: methanol : glacial acetic acid (97 : 7 : 1) 
Mobile phase B - ethyl acetate 
4.1.4.4 PREPARATION OF VAN URK'S REAGENT 
CHAPTER 4 
Van Urk's reagent was used for visualising the indoles after these have been separated by 
TLC. 1 gram of dimethylbenzaldehyde (DMBA) was dissolved in 50 ml of25 % Hcl and 50 
ml of95 % ethanol. 
4.1.4.5 THE PINEAL ORGAN CULTURE TECHNIQUE 
The pineal organ culture technique was followed as described by Morton\(I990). The rats 
I 
were sacrificed invasively. The intact pineal gland was then rapidly excised and incubated at 
37°C in medium containing 8 Jil e4C]5-HT for 24 hours. During the incubation period, the 
pineal gland metabolised the radioactive 5-HT and this was followed by release of the 
radiolabelled metabolites into the culture medium. After the incubation period, the pineal 
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Table 4.1 The composition of the BGJB culture medium modified from Fitton Jackson 
AMINO ACIDS 
L-Alanine 250.00 
L-Arginine 175.00 
L-Aspartic Acid 150.00 
L-Cysteine HCI 90.00 
L-Glutamine 200.00 
Glycine 800.00 
L-Histidine 150.00 
L-Isoleucine 30.00 
L-Leucine 50.00 
L-Lysine HCI 240.00 
L-Methionine 50.00 
L-Phenylalanine 50.00 
L-Proline 400.00 
L-Serine 200.00 
L-Threonine 75.00 ,1 
L-Tryptophan 40.00 
L-Tyrosine 40.00 
DL-Valine 65.00 
INORGANIC SALTS 
Dihydrogen sodium orthophosphate 90.00 
Magnesium sulphate (7H20) 200.00 
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Sodium bicarbonate 3500.00 
Sodium chloride 5300.00 
. OTHER COMPONENTS 
Calcium Lactate 555.00 
Glucose 10000.00 
Phenol red 20.00 
Sodium acetate 50.00 
VITAMINS 
(1-Tocopherol phosphate 1.00 
Ascorbic acid 50.00 
Biotin 0.20 
Calcium pantothenate 0.20 
Choline pantothenate 50.00 
Folic acid 0.20 
Inositol 0.20 
Nicotinamide 20.00 
p-Aminobenzoic acid 2.00 ,I 
Pyridoxal phosphate 0.20 
Riboflavin 0.20 
Thiamine HCI 4.00 
Vitamin 0.04 
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glands were flicked out of the medium and stored at -20°C. An aliquot of the medium which 
contained the radioactive metabolites of the pineal gland was analysed using TLC and 
quantified by liquid scintillantion technique. 
4.1.4.6 SEPARATION OF PINEAL INDOLES BY TLC 
TLC plates {IO x 10) were used for the separation of indoles. Using a pencil, an arrow 
pointing forward and the other pointing to the right were drawn on top right hand corner of 
the plate. The first arrow showed the direction of movement of mobile phase A and the latter 
to the direction of mobile phase B. 10 j1l of the medium was then spotted 1 cm from the 
bottom and from the left hand side of the plate with gentle continual stream of nitrogen to 
form a 4 - 5 mm spot. When the spot was dry, 5 j11 of the standard solution was spotted on 
top of the first spot and dried as before. 
The plates were then developed in the darkness in solvent A to about two thirds of the first 
direction. Plates were rapidly dried with nitrogen on both sides and immediately plac!ed again 
in the darkened developing tank for the second development in solvent A. The plates were 
dried with nitrogen and placed in solvent B for development in the darkness in the second 
direction pointing to the right and allowed the solvent to migrate half-way up the plate. The 
plate was dried and sprayed with van Urk's reagent to visualise the indoles. The plates were 
then placed in a 60°C oven for two minutes and thereafter the spots were identified. The 
113 
CHAPTER 4 
silica gel containing the radioactive metabolites was scraped off the plate and placed in 
counting vials containing 1 ml95 % ethanol. The vials were put in a shaker for an hour and 
3 ml of scintillation fluid was then added to the cocktail and left to stand for 30 minutes. The 
products were counted in a Beckmann LS 2800 scintillation counter. 
4.1.5 RESULTS 
The results were expressed as dpm's of radioactive NAS and aMT. The solid line represents 
the mean and the dotted line represents the standard errorofthe mean (SEM). Figure 4.2 and 
figure 4.4 show that there are clear inter-individual differences in scoto-phase NAS and aMT 
production. However, the intermediate group of producers is not prominent during the scoto-
phase. In photo-phase samples, the distinction between high and low producers ofNAS and 
aMT is not as substantial as in scoto-phase (figure 4.3 and figure 4.5). It is the intermediate 
group that is distinctive during the photo-phase. 
,I 
4.1.6 DISCUSSION 
Pineal indoleamines exhibit a distinctive and well described circadian rhythmicity. Pineal NAS 
levels are low during the day and elevated during at night. This rhythm is due to the activity 
of NAT (Klein and Weller, 1970). The pineal aMT circadian rhythm is in phase with that of 
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Figure 4.2 Pineal aMT levels analysed using the organ culture technique and TLC: 
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Figure 4.3 Pineal aMT levels analysed using the organ culture technique and TLC: 
Photo-phase samples were taken from a mixed population; n = 20 
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NAT and NAS respectively. 
The magnitude of the nocturnal rise in pineal aMT varies among species (Reiter, 1988). The 
results obtained from this study were in agreement with this report. The inter-individual 
variation ofNAS and aMT was shown to exist in both the scoto-phase and the photo-phase 
samples (figure 4.2 and figure 4.5), with a more pronounced effect during the scoto-phase. 
The possible explanation for the clear distinction between high and low producers during the 
scoto-phase is the rise in pineal aMT and NAS production during the scoto-phase. An 
existence of an intermediate group was apparent during the photo-phase since N AS and aMT 
production are low during this period. 
4.2 DETERMINATION OF THE EFFECT OF 6-MBOA ON PINEAL 
INDOLE BIOSYNTHESIS 
4.2.1 INTRODUCTION 
The objective of this experiment was to determine whether 6-MBOA would have an effect 
on the biosynthesis of the pineal indoles in vivo. This was prompted by the observation made 
by Daya et. al. (1990) and Daya and Tandt (1993), which showed that 6-MBOA induces 
NAT activity and aMT biosynthesis with a concomitant rise in cAMP levels at high 
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concentrations ( 1 mM). However, no effect was shown on the activity of IDOMT by these 
authors. 
The pineal organ culture and TLC technique were employed for quantifYing the pineal indoles as 
described by Morton (1990). 
4.2.2 ANIMALS 
Male Wistar rats of the albino strain weighing 200 -250 g were used and maintained as described 
in section 2.2. Animals were sacrificed between 12hOO and 13hOO. The pineals were removed as 
described in section 4.1.2. 
4.2.3 CHEMICALS AND MATERIALS 
Chemicals and reagents used were as describ,ed in section 4.1.3. 
4.2.4 REAGENTS AND METHODOLOGY 
Reagents were prepared as described from section 4.1.4.1 to section 4.1.4.4. The methodology 
was followed as described from section 4.1.4.5 to section 4.1.4.6. 
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4.2.5 RESULTS 
The results for the determination of the effect of 10 mg / kg on pineal indole biosynthesis were 
expressed as dpm's / 10 ,ul medium. Statistical differences were determined using the Student's 
t-test P values less than 0.05 were taken as significant. The radioactive 5-HT added as the 
precursor for the pineal indoles tested was significantly reduced in 6-MBOA treated animals (P 
< 0.05). NAS production was insignificantly elevated. However, aMT production was significantly 
increased after 6-MBOA administration (P < 0.01). No significant change was observed in other 
indoleamines, 5-HIAA, 5-HTOH, 5-MIAA and 5-MTOH. 
4.2.6 DISCUSSION 
Pineal indole biosynthesis starts by uptake of tryptophan form the blood circulation. Within the 
pinealocyte, tryptophan is hydroxylated to 5-HTP by the enzyme TH. Ther~after, the enzyme 
aromatic amino acid decarboxylase decarboxylates 5-HTP to form 5-HI. Once 5-HT (s formed, 
5-HT is biotransformed in one of three possible routes: 
(i) Some 5-HT is deaminated to 5-HIAA and 5-HTOH by the enzyme MAO. These 
hydroxyindoles may be methylated by HIOMT to form 5-MIAA and 5-MTOH. 
(ii) Some 5-HT may be directly methylated by HIOMT to form 5-methoxytryptamine 
(iii) The major route of 5-HT is its conversion to aMT via acetylation by the enzyme 5-HT 
-
NAT to yield NAS which is then methylated by HIOMT to form aMI. This study dealt 
only with routes (i) and (iii). 
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6-MBOA, structural analogue of5-HT and aMT has been reported to increase aMT production 
in vitro at 10-3 M concentrations (Daya and Tandt, 1993). The results of this study somehow 
confirm this finding in that, aMT production was significantly increased proportionally with the 
decrease in exogenous 5-HT and an insignificant increment in NAS production, an immediate 
precursor of aMT. The possible explanation for the considerable reduction in exogenous 5-HT 
could be that, 6-MBOA has been shown to stimulate NAT activity, a rate limiting enzyme in aMT 
biosynthesis in vitro at pharmacological concentrations (Daya et. ai., 1990). 
From the results, the pathway of 5-HT metabolism which involves deamination of 5-HT to 5-
HIAAand 5-HTOHby MAO and the subsequent methylation of these hydroxyindoles to 5-MIAA 
and 5-MTOH appeared not to be affected by 6-MBOA treatment. One optional explanation could 
be that, 6-MBOA does not have an effect on pineal MAO. Another possible explanation could be 
that, since the aMT route for 5-HT metabolism is stimulated by 6-MBOA and aMT biosynthesis 
being the major route on its own for 5-HT metabolism, the other routes are olltcompeted for the 
substrate thus leading to maintenance of the normal biosynthesis of the other indoleathines. 
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DETERMINATION OF THE EFFECT OF 6-MBOA ON 
PINEAL MELATONIN (aMT) PRODUCTION EMPLOYING 
COMPETITIVE ELISA TECHNIQUE 
5.1 INTRODUCTION 
Melatonin (aMT), a major hormone of the pineal gland is synthesized from the amino acid tryptophan. 
aMT has its highest levels during the night time. Circulating aMT is almost exclusively of pineal origin 
since in some cases, plasma concentrations at night in particular are depressed and undetectable after 
1 
pinealectomy. Human plasma melatonin levels show a marked individual variation. DaYlime levels are 
very low and are in the range of 10 pg I ml in the morning hours whereas night time levels exceed 30 
pg I m!. aMT is metabolised in the liver to 6-hydroxymelatonin which is conjugated to either 
glucuronide (20 - 30 %) or sulphate (60 - 70 %) (http://www.IBL-Hamburg.com). 
Several researchers have proposed that circadian rhythms playa vital role in the etiology of affective 
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disorders (Halberg, 1967; Wehr and Goodwin, 1983). Depression symptomology exhibits a diurnal 
variation with exacerbation early in the morning and improvement in the evening. Depressive 
symptoms also vary seasonally. aMT rhythm thus provides a useful marker in depressive illness. The 
secretion of aMT in blood and urine follows a 24 hour rhythm. The majority of studies indicate that 
aMT secretion is reduced in depressed patients although conflicting results have been reported. A 
functional deficiency ofNA, 5-HT or both has the potential to lower pineal aMT production (Arendt, 
1989). 
There are a number of methods employed to measure aMT blood plasma levels and these include 
radioimmunoassay (RIA) (Rollag and Niswender, 1976), gas chromatography (GC) and mass 
spectrometry (MS) (Lewy and Markey, 1976). In this study, the circadian pattern and the effect of 
6-MBOA in endogenous pineal aMT production was measured and the method of competitive ELISA 
was employed. 
aMT ELISA is a competitive enzyme immunoassay for the quantitative analysis of aMT in serum, 
plasma and tissue homogenate which initially requires extraction. The assay procedure follows the 
basic principle for competitive immunoassays whereby there is competition between a biotinylated 
and non-biotinylated antigen for a fixed number of antibody binding sites. Bound biotinylated antigen 
to the antibody is inversely proportional to the analyte concentration ofthe sample. When equilibrium 
is reached, the free biotinlyated antigen is removed by a washing step and the bound antibody to the 
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biotinylated antigen is determined by employing an anti-biotin alkaline phosphatase enzyme as a 
marker and p-nitrophenylphosphate as a substrate. The quantification of unknown samples is obtained 
by comparing the enzymatic activity of unknowns with a response curve prepared by using known 
standards (http://www.IBL-Hamburg.com). 
5.2 ANIMALS 
Male Wi star rats of the albino strain weighing 200 - 250 g were randomly assembled into two groups 
of five and maintained as previously described in section 2.2. Injections of 10 mg/kg of 6-MBOA 
were done as described in section 2.2.1. For photo-phase experiments, animals were sacrificed 
between 12hOO and 13hOO and for scoto-phase experiments animals were sacrificed between OOhOO 
and 01hOO under a dim red light. Pineal glands were removed as described in section 4.1.2. 
Immediately after removal, the pineals were immediately stored in liquid nitrogen and kept frozen at 
-70°C until required. 
5.3 CHEMICALS AND REAGENTS 
5.3.1 CHEMICALS 
All chemicals were purchased from Research Diagnostics Inc., Pleasant Hill Rd, Flanders and were 
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of the highest purity. 
5.3.2 REAGENTS 
ASSAY BUFFER : Dilute 50 ml phosphate buffer with tween and stabiliser then 
dilute 1: 10 with bidistilled water. 
ANTISERUM : Dissolve contents of each vial in 2 ml of bid is tilled water. 
MELATONIN-BIOTIN : Dissolve contents of each vial in 2 ml of assay buffer. 
STANDARD A-F : Dissolve contents of each vial in 2 ml of bidistilled water and store 
aliquotes at -20°C. 
CONTROL SERUM 1 & 2 : Dissolve contents of each vial in 2 ml of bidistilled water and store 
aliquotes at -20°C. 
ENZYME CONJUGATE : Dilute 250 ,ul anti-biotin-alkaline phosphatase in TRIS buffer with 
stabilizers and dilute 1: 81 with Assay Buffer 1 
I 
5.4 PREPARATION OF THE PINEAL HOMOGENATE 
The frozen pineal glands (-70°C) were slowly thawed on ice and sonicated in 500,u1 of ice cold 0.9 
% saline for two seconds. 
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5.5 aMT EXTRACTION PROCEDURE 
Extraction columns for each sample were placed into glass tubes. Two x 1 m1 of absolute methanol 
were added to the columns and centrifuged for one minute at 200 x g. After centrifugation, two x 1 
m1 of distilled H20 were added to columns and centrifuged for 1 minute as before. Immediately after 
centrifugation, the pineal homogenate was applied to avoid the columns from getting dry and 
centrifuged for 1 minute at 200 x g. Thereafter, the columns were washed with two x 1 m1 of 10 % 
methanol in distilled water (v/v) and the columns centrifuged for 1 minute at 500 x g. The columns 
were then placed into clean glass tubes and 1 m1 of undiluted methanol was added to the columns 
(undiluted methanol was used for extraction of the product) and centrifuged for 1 minute at 200 x g. 
Subsequently after centrifugation, the columns were removed from the glass tubes. Methanol was 
evaporated to dryness and the sample was reconstituted with 0.15 m1 of distilled H20. The mixture 
was vortexed for 1 minute and immediately assayed afterward. 
5.6 ASSAY PROCEDURE 
To 50,ul of each extracted standard, controls and samples, 50,u1 of melatonin-biotin and subsequently 
50 ,ul of antiserum were added. The plate was sealed with adhesive foil and incubated overnight at 
2 - 8°C. The wells were washed three times with assay buffer. 200 m1 ofPNPP substrate solution 
was pipetted into the wells followed by incubation at room temperature for 20 to 40 minutes. The 
125 
CHAPTERS 
substrate reaction was stopped by adding 50 ,ul pf stop solution. Optical density was read at 405 nm 
within 60 minutes after termination of the reaction. 
5.7 RESULTS 
The logarithmic concentrations of the standards were plotted against the corresponding optical 
densities. Each sample was done in duplicate. The concentration of the samples were read directly 
from the standard curve by using the average optical density of each sample. Statistical differences 
between the two groups were determined using the Student's t-test. 
The results obtained from this study showed that the pineal aMT production is circadian with peak 
levels occurring during the scoto-phase (figure 5.2). The values obtained for photo-phase samples 
were ± 2.48 pg/ml and for scoto-phase samples only ± 17.67 pg/ml. Administration of 10 mg/kg 6-
MBOA lead to a significant augmentation ofaMT production in both phases\(figure 5.3 and figure 
5A). J 
5.8 DISCUSSION 
aMT is synthesized from 5-HT, which is present in the pineal gland at higher concentration than any 
other tissue, with the possible exception of the raphe nucleus, the location of serotonergic cell bodies 
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Figure 5.1 Melatonin standard curve using competitive ELISA 
[Data represents mean a/triplicate determinants; r = 0.953] 
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(Klein et. ai., 1997). The conversion of5-HT to aMT involves two enzymes, NAT andHIOMT. The 
first enzyme N-acetylates 5-HT to form NAS and the second enzyme O-methylates NAS to form aMT 
(Klein et. ai., 1997). The rhythm in aMT biosynthesis is generated by a rhythm in the NAT activity 
(Klein and Weller, 1970). An increase in NAT activity at night decreases the pineal 5-HT and 
increases the concentration ofNAS (Klein et. ai., 1997). Changes in the activity ofHIOMT have little 
influence on the large changes in aMT production that drive the aMT rhythm (Klein, 1985). 
The results of this study validate the above reports as more aMT was produced during the scoto-
phase. 6-MBOA has been shown to possess properties ofa weak p-adrenergic agonist in vitro (Sweat 
and Berger, 1988). 6-MBOA has also been shown to stimulate NAT activity and aMT respectively. 
The present study indicates that, 6-MBOA further enhances aMT production in vivo. 
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SUMMMARY AND CONCLUSION 
6.1 SUMMARY 
6.1.1 CHAPTER 2 
Hepatic TDO activity was determined using a method described by Badawy et. al. (1973, 1975 
and 1980). The principle for the assay involves the incubation of the crude enzyme with its 
substrate, L-tryptophan (0.03 M). For determination ofthetotal enzyme activity, haem was added 
to activate the non-active form of the enzyme. The difference between the to~al enzyme and the 
" 
holoenzyme activity was used as a measure of the apoenzyme activity. The product formed, L-
kynurenine was used as a measure ofTDO activity. 
The results obtained show that hepatic TDO activity is subject to a circadian rhythm. The highest 
enzyme activity occurs during the photo-phase and the minimum activity during the scoto-phase. 
This circadian variation was observed in apoenzyme activity. 
6-MBOA inhibited hepatic TDQ activity in vivo in !Joth phases with a more pronounced effect 
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during the photo-phase. Holoenzyme activity was shown to be increased during the scoto-phase 
in both treated and untreated samples. From these results it can be deduced that the mode of 
inhibition of 6-MBOA is through: 
(i) the interference in the conjugation of the apoenzyme with haem 
(ii) improper interactions between 6-MBOA and the catalytic site ofTDO caused by the lack of 
the CHNH2COOH functional group and 
(iii) H-bonding formed between CH3 and haem pocket leading to loss of catalytic activity ofTDO. 
It can therefore be concluded that 6-MBOA is a pQtential antidepressant as it could increase the 
availability ofL-tryptophan to the brain by inhibiting hepatic TDO activity which is a prerequisite 
for the biosynthesis of an essential biogenic amine, 5-HT, in depression. 
6.1.2 CHAPTER 3 
,1 
5-HT is synthesised from tryptophan by the enzyme TH which is rate limiting in 5-HT biosynthesis 
(Reiter, 1981). After the biosynthesis and release of 5-HT from presynaptic vesicles, 5-HT is 
either: 
(i) oxidised by MAO and converted to 5-HIAA, an essential metabolite of 5-HT or 
(ii) taken into the presynaptic vesicles by re-uptake or 
(iii) binds to the postsynaptic r~ceptors. 
Competitive ELISA was used fOr measuring brain 5-HT levels. This technique is very sensitive 
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as concentration of ng / mg tissue of 5 -HT were obtained. The results of the present study show 
a rise in 5-HT levels induced by in vivo administration of 6-MBOA in rats. 
It has also been shown that an increase in 5-HT biosynthesis caused by 6-MBOA does not only 
enhance 5-HT production and TH activity, however, 6-MBOA also causes inhibition of 5-HT 
binding to synaptosomal membrane at specific 5-HT concentrations. 5-IDAA production was also 
significantly increased after 6-MBOA administration. 
Drugs which increase 5-HT concentration, including 6-MBO A can be clinically used for treatment 
of affective disorders However, the possibility of deyelopment of side effects should be taken into 
consideration. 
6.1.3 CHAPTER 4 
\ 
Relative proportion of metabolites formed during the 24 hour incubation of [14C]5-HT with rat 
,I 
pineal glands in culture medium was assessed by separation of the respective indoles using TLC 
and the radioactive metabolites quantified using a Beckman LS-2800 scintillation counter. 
Results obtained from this study show at 6-MBOA has variable effects when administered to the 
rat. The only significant change caused by 6-MBOA in the production of pineal indoles is 
the synthesis of aMT. This finding is in accordance with the in vitro studies done on the assessment 
-. of the pineal indoles NAS and aMT production, whereas NAS did not show any significant 
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change. Furthermore, a study to investigate the existence of inter-individual variation in pineal 
NAS and aMT production showed that the scoto-phase samples which portray high levels of the 
two indoles can be used as the models for dividing animals into high and low NAS and aMT 
producers. The third group ofNAS and aMT producers, the intermediate group can be clearly 
distinguished in photo-phase samples. 
6.1.4 CHAPTER 5 
Competitive ELISA technique was employed for estimation of endogenous pineal aMT 
production. This technique is very sensitive and specific as concentrations of aMT in picogram 
levels can be detected. The rhythm in circulating aMT is closely related to the environment, 
specifically to light and darkness (Arendt, 1995). The results obtained from this study showed a 
circadian production of aMT with higher levels occurring during the scoto-phase. 6-MBOA 
administration lead to an increment in aMT production. It can be concluded that 6-MBOA has 
\ 
potential as a possible antidepressant since low levels of aMT are reported in patients suffering 
" 
from winter depression, which is known as seasonal affective disorder (Rosenthal et. ai., 1984). 
6.2 CONCLUSION 
Depression is associated with abnormal sensitivity of serotonergic and noradrenergic neuronal 
receptors (Johnson and Lydiard, 1998). Surveys in the USA over the past fifteen years have 
shown that fewer than half of those who develop depressive illness seek treatment for the illness 
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(Bucholz and Dinwiddie, 1989; Dew et. ai., 1991). Because nearly all the literature describing 
affective disorders is based on treated samples, very little is known about the larger group with 
untreated depression. 
Antidepressant medications are the main pharmacological treatment for acute severe depression. 
The efficacy of these medications in patients with unipolar disorders is well established and the 
benefit of continued treatment for prevention of future relapse is well documented (Prien et. aI., 
1984). However, these medications have been associated with the onset of mania (prief et. ai., 
1973; Prien et. ai., 1984) or cycle acceleration (Kukupulos et. ai., 1980) in some but not all 
(Angst, 1985) reports. 
The present study has provided support on the hypothesis that 6-MBOA may act as a possible 
antidepressant. This has been shown by the results which indicate the inhibition of the liver TDO 
activity with subsequent rise in 5-HT biosynthesis. However, modification needs to be done on 
the enzyme TH which is the rate limiting enzyme in 5-HT biosynthesis. TH reqiIires pretreatment 
, 
with dithiothreitol-F e2+ for maximum activity ~nd it was not included in this study. Further studies 
on the effect of 6-MBOA on the re-uptake system of 5-HT also needs to be done since more 
attention with regards to the use of S SRI=s for treatment of depression is currently implemented. 
There is also an increasing likelihood that 6-MBOA may be a potential antidepressant as animals 
produced more pineal aMT after treatment with this drug. Pineal aMT biosynthesis has been 
- . proposed as a measure of the overall effect of antidepressant drugs on nor-adrenergic NT 
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(CheckIey et. a/., 1986). aMT biosynthesis depends on NA release which stimulates nor-
adrenergic receptors that stimulate adenylate cyclase which subsequently stimulates NAT activity, 
which is the rate limiting enzyme in aMT biosynthesis. 6-MBOA has potential as a possible 
antidepressant and therefore should be investigated for antidepressant activity. 
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